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Abstract
Markus Lagus. Molecular mechanisms of sleep and mood. National Institute for 
Health and Welfare (THL), Research 100. 156 pages. Helsinki, Finland 2013.
ISBN 978-952-245-850-6 (printed), ISBN 978-952-245-851-3 (pdf)
Background Sleep disturbances and mood alterations are highly interrelated. 
The majority of patients suffering from depression report a reduced sleep quali-
ty. Inversely, people with sleep complaints are at elevated risk to develop depres-
sion. The complex regulation of these phenomena involves several brain areas and 
mechanisms. The susceptibility to change in this system is influenced by several fac-
tors, such as age and stressful lifestyle that are considered in this study.
Hypothesis The hypothesis of this study was that sleep and mood share common ge-
netic/molecular regulatory networks and that both are also regulated by epigenetic 
mechanisms and neural plasticity.
Methods The studies were conducted both on humans and using an animal model 
for depression. In the animal model we measured  the genome wide expression of ge-
nes in different brain areas of clomipramine-treated pups and adults.  Using these da-
ta we conducted both individual area and inter-area network analyses of basal foreb-
rain, frontal cortex, hypothalamus and hippocampus. We also measured the amount 
of BDNF, one of the plasticity-related factors, in sleep restriction and under aging. In 
the human study we conducted epigenetic analysis of the serotonin transporter ge-
ne and related the epigenetic changes to stress in a stressful working environment. 
Results In the models investigated changes were observed on the system, protein, 
transcript and transcriptional regulatory levels. Inter-tissue pathways related to sy-
naptic transmission, regulation of translation and ubiquitinylation were disrupted. 
The involved pathways are within the cellular components of the axons, growth 
cones, melanosomes and pigment granules. The disturbed networks are centred 
around serotonin, Mn(II) and Rhoa. In the basal forebrain the imbalance in ge-
ne expression is widely controlled by CREB1. Some of the changes seem to be epi-
genetically induced by sleep deprivation and stress. Individuals working in a high 
stress environment have significantly less methylation in the promoter area of sero-
tonin transporter gene SLC6A4, as compared to individuals working in a low stress 
environment. We also found that the expression of cortical BDNF correlated with 
the recovery non-REM (NREM) slow wave activity (SWA) response, and that both 
the cortical BDNF and the SWA response to sleep deprivation were decreased in the 
aged animals, as were the changes in sleep latency.
Conclusions The disturbances in the models investigated, arise, largely, but not so-
lely, due to disruption in neurological systems previously related to the regulation 
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of sleep and mood. Novelty value could be ascribed to findings that suggest involve-
ment of inter-tissue networks, and more precisely, imbalance of melanosome related 
gene expression and gene networks connected to Mn(II). The stress induced demet-
hylation of the SLC6A4 promoter suggests a mechanism for the body to cope with 
prolonged excessive stress. The downside of this coping mechanism is the possibility 
that this reprogramming increases the long-term risk for mood disorders. The fin-
dings in the sleep deprived aging rats support the hypothesis that the age related dec-
rease in homeostatic NREM SWA is related to a reduced sleep need.
Keywords: sleep, mood, genes, pathways, networks 
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Tiivistelmä
Markus Lagus. Molecular mechanisms of sleep and mood [Uni- ja mielialahäiriöi-
den molekyylitausta]. Terveyden ja hyvinvoinnin laitos (THL), Tutkimus 100. 156 
sivua. Helsinki 2011.
ISBN 978-952-245-850-6 (painettu), ISBN 978-952-245-851-3 (pdf)
Tausta Uni- ja mielialahäiriöt ovat tiiviisti kytköksissä toisiinsa. Valtaosa masennus-
potilaista ilmoittavat myös unen laadun heikentyneen. Käänteisesti, univaikeuksista 
kärsivät henkilöt ovat alttiimpia masennukselle. Näiden ilmiöiden säätely on moni-
mutkainen ja tapahtuu usean mekanismin avulla monessa eri kohdassa aivoja. Use-
at eri tekijät, kuten rasittava elämäntyyli ja ikä jotka ovat huomioitu tässä tutkimuk-
sessa, vaikuttavat tähän järjestelmään.
Hypoteesi Tämän tutkimuksen hypoteesi oli että unea ja mielialaa säätelevät sa-
mat geneettiset ja molekyylitason järjestelmät joita vuorossaan säätelee epigeneetti-
set mekanismit ja neuronaalinen plastisuus.
Menetelmät Tässä tutkimuksessa käytetään sekä ihmisnäytteitä että eläinmalleja. 
Masennusta jäljittelevässä eläinmallissa mitataan perimänlaajuisesti usean eri ai-
voalueen geeniekspressiota. Näihin mittaustuloksiin perustaen, suoritettiin analyy-
sejä sekä yksittäisissä aivoalueissa että geeniverkkoanalyysejä useista aivoalueista. 
Toisessa eläinmallissa mitattiin plastisuusgeenin BDNF:än ilmentymistasoja ikään-
tymisessä ja olosuhteissa joissa unta häiritään. Ihmistutkimuksessa tarkkaillaan 
muutoksia serotoniinikuljettajageenin epigeneettisessä säätelyssä suhteessa rasitta-
vaan työympäristöön.
Tulokset Tutkituissa malleissa todetaan muutoksia niin järjestelmä-, proteiini-, 
transkripti- että transkriptiota säätelevällä tasolla. Useita aivoalueita kattavia geeni-
polkuja liittyen synapsien välitykseen, translaation säätelyyn ja ubiquitinylaatioon 
todetaan muuttuneen. Muuttuneet verkostot keskittyvät Mn(II) ja Rhoa:n ympä-
rille. Basaalisissa etuaivoissa muuttunut geeniekpressiotasapaino on laajalti CREB1 
säätelemä. Jotkut muutokset näyttävät johtuvan univajeen ja stressin käynnistämästä 
epigeneettisestä säätelystä. Yksilöissä jotka työskentelevät rasittavassa työympäris-
tössä todetaan alhaisempi metylaatioaste serotoniinikuljettajageenin (SLC6A4) pro-
mootterialueella, verratuna vähemmän rasittavassa työympäristössä työsketeleviin. 
Todetaan myös että aivokuoressa tapahtuva BDNF ekspressio korreloi palautusunen 
non-REM (NREM) matalaaaltopituisen aktiviteettivastineen (SWA) kanssa, ja että 
BDNF ekspressio, SWA vastine sekä muutokset univiiveessä heikentyvät iän myötä.
Johtopäätökset Häiriöt näissä tutkituissa malleissa johtuvat pääasiallisesti muutok-
sista jo ennestään tunnetuissa unta ja mielialaa säätelevissä neurologisissa järjes-
telmissä. Todettakoon kuitenkin että löydökset jotka viittaavat eri aivoalueita yh-
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distävissä järjestelmissä, eritysesti melanosomeihin liittyvässä geeniekspressiossa 
sekä Mn(II) liittyvien verkkojen olevaan epätasapainoon ovat ennennäkemättömiä 
ja avaavat uusia alueita uni- ja mielialatutkimuksessa. Stressin aiheuttama demety-
laatio SLC6A4 promootterialueella taas osoittaa kehon menetelmää selvitä pitkäai-
kaisen stressin kanssa. Tämän mekanismin haittapuolena saattaa kuitenkin olla että 
se pidemmän päälle lisää riskiä sairastua mielialahäiriöön. Ikääntyneissä eläimissä 
suoritetut unihäirintäkokeet taas tukevat hypoteesiä jonka mukaan ikääntymiseen 
liittyvä homeostaattisesen NREM SWA vastineen väheneminen  johtuisi pienenty-
neestä unentarpeesta.
Avainsanat: uni, mieliala, geenit, polkuanalyysi, geeniverkko
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1  Introduction
Sleep, mood and stress are all phenomena that express fluctuations in both frequen-
cy and duration, as well as in intensity and quality. Limits have to be defined for 
changes to qualify as abnormal. This means that either large sample size or radical 
models have to be used when studying these phenomena. The absence of definite 
boarders nevertheless does not mean that individuals suffering from disturbances in 
any of these phenomena could be left unattended to. The main focus in this study is 
the effect of changes in sleep and stress, with the outcome of depressed mood. Most 
of the work represented in this study is presumption free, with the exception of the 
candidate gene approaches used for the BDNF and SLC6A4 studies in relation to 
mood, sleep and age, respectively stress. Nevertheless, the findings to a large extent 
comprised of changes in molecular systems, such as the cholinergic, glutamatergic, 
serotonergic, GABAergic and components of the hypothalamic-pituitary-adrenal 
(HPA) axis, previously related to the regulation of both sleep and mood.
1.1  Sleep
Sleep is a reversible state of reduced consciousness and response to outside stimuli. 
Most animals studied present a state of sleep, whereas in some the term “rest” is pre-
ferred to avoid complications with the definition of sleep (Cirelli & Tononi, 2008). 
Mammalian sleep is divided into two distinctive types of sleep; rapid eye movement 
(REM) sleep and non-rapid eye movement (NREM) sleep. The characteristics of REM 
sleep are; a high activity in the high frequency spectra of the electroencephalogram 
(EEG) and rapid eye movements, as implied by the name of the sleep type. In NREM 
sleep the eyes remain still and the EEG reveals low frequency waves of high amplitude. 
The NREM sleep can be further divided into three stages (N1, N2, N3). During the 
progression from stage N1 to N3 the frequency drops and the amplitude rises. Stage 
N3 is also referred to as slow wave sleep (SWS). Sleep duration and timing is regulat-
ed by two different components: the homeostatic, and the circadian component. The 
homeostatic sleep pressure rises according to the time spent awake, whereas the sleep 
pressure arising from the circadian component varies during the daily cycle. The addi-
tive effects of the two components amounts to the total sleep pressure (Borbely, 1982).
1.2 Major depressive disorder (MDD)
MDD is a common mental disorder with a worldwide lifetime prevalence estimate of 
8-12% (Andrade et al., 2003). Depression is the leading cause of disability as meas-
Introduction
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ured by years lived with disability (YLDs) and in year 2002 MDD was estimated to 
be the 4:th leading contributor to the global burden of disease (GBD), whereas it is 
estimated to be ranked 2:nd on the list by year 2030 (Mathers & Loncar, 2006). To 
some extent the high GBD for MDD is due to the high mortality by suicide. A meta-
analysis showed that 87.3% of suicide cases had been diagnosed with a mental dis-
order, mainly MDD (Kessler, 2007) and another meta-analysis showed that 16-19% 
of MDD diagnosed patients complete suicide (Wulsin, Vaillant, & Wells, 1999). The 
healthcare costs for MDD are substantial and it has been suggested that the devel-
opment of cost-effective treatments for mild disorders might prevent a large propor-
tion of future serious disorders (Kessler, 2007).
1.3 The impact of disturbed sleep on mood
The existence of interplay between sleep and mood is hard to deny. People that report 
sleep complaints are at 3-4 times the elevated risk of developing a new major depres-
sion within one year (Breslau, Roth, Rosenthal, & Andreski, 1996; Ford & Kamerow, 
1989). Sleep disturbances are key features of depressive symptomatology and up to 
90% of depressed patients complain of poor quality of sleep (Tsuno, Besset, & Ritch-
ie, 2005). The mood of healthy individuals is affected by both acute and cumulative 
partial sleep deprivation (SD) (Ferrara & De Gennaro, 2001). The instant, but unfor-
tunately temporary, antidepressant effect of SD in depressed patients (Wirz-Justice & 
Van den Hoofdakker, 1999) is, inversely, another example of the interplay. Yet very lit-
tle is known about the causal nexus of disturbed sleep and depressed mood, especial-
ly on a molecular level. One way to address this relationship is to use controlled SD, 
in either healthy volunteers or animals. Another way is to observe a large cohort, with 
data of the parameters of interest, linked to it.
1.4 The impact of stress on mood
An overall trend in the increase of work stress can be observed in Europe (Eurofound, 
2012). A high work strain and stressful working environment significantly increases 
the risk of a depressive episode (Blackmore et al., 2007; Kopp, Stauder, Purebl, Jansz-
ky, & Skrabski, 2008; Melchior et al., 2007). That chronic stress has a negative effect on 
mood is well known, but the molecular mechanisms underlying the connection are 
under dispute. Recent findings have revealed the vastness of adult neurogenesis and 
stress has been shown to be one of the most potent environmental parameters that 
suppress adult neurogenesis (Mirescu & Gould, 2006). This suppression of neurogen-
esis, especially in the HIP and FCX, is thought to increase vulnerability to depression 
and (according speculations), also sleep disruption would exert its negative effects on 
mood via the same mechanism (Lucassen et al., 2010).
Introduction
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On a molecular level the serotonergic system, the serotonin transporter gene 
(SLC6A4) in particular, has received much attention in stress related studies. The 
SLC6A4 encodes the serotonin transporter protein 5HTT, responsible for the reup-
take of 5-HT to the presynaptic neuron. 5HTT determines the magnitude and du-
ration of serotonergic response and is thus central to the fine-tuning of serotonergic 
neurotransmission (Mossner et al., 2000). One of the mechanisms regulating 5HTT 
activity is regulation at the level of transcription by DNA methylation. This methyl-
ation of the SLC6A4 promoter is associated with a decrease in SLC6A4 mRNA and 
thought to add to the vulnerability to psychiatric illnesses (Philibert et al., 2007).
Furthermore, the serotonergic system as a whole is gaining an increasing 
amount of attention in all the subsystems observed in this study: sleep (Ursin, 2002), 
depression (Blier & de Montigny, 1994), stress and ageing (Rodriguez, Noristani, & 
Verkhratsky, 2012).
1.5 Age – sleep
Changes in circadian timing and the regulation of homeostatic sleep pressure, accom-
panied by changes in sleep quality and architecture, occur with age. The total sleep time 
is reduced and, accordingly, the total amount of time spent awake, in episodes, after 
sleep onset is increased with age (Buysse, Monk, Carrier, & Begley, 2005). The sleep ef-
ficiency, percentage of slow-wave sleep, percentage of REM sleep and REM latency de-
crease with age, while overall sleep latency (SL), proportion of stage 1 sleep, proportion 
of stage 2 sleep, increase with age.  However, only sleep efficiency continues to decrease 
after 60 years of age (Ohayon, Carskadon, Guilleminault, & Vitiello, 2004).
In detail, the decrease in slow-wave activity (SWA) at electroencephalograph-
ic (EEG) power between 0.5 and 4 Hz, during NREM sleep is a marker of sleep 
need and SWA increases according to wake quality (Huber, Tononi, & Cirelli, 2007; 
Wigren, Schepens, Matto, Stenberg, & Porkka-Heiskanen, 2007; Vyazovskiy & To-
bler, 2005) and time spent awake before falling asleep (Achermann, Dijk, Brunner, & 
Borbely, 1993; Borbely, 1982) and decreases during subsequent recovery sleep. Plas-
tic processes that occur during wakefulness increase sleep pressure and result in an 
increase in synaptic strength, which is renormalized during sleep and a recent hy-
pothesis suggests that changes in SWA follow changes in cortical synaptic strength 
(Tononi & Cirelli, 2003, 2006). The expression of genes related to synaptic plastici-
ty, e.g. the brain-derived neurotrophic factor (BDNF), have been shown to increase 
in the cortex during spontaneous and prolonged waking, as compared to the state of 
sleep (Cirelli & Tononi, 2000), in accordance with the aforementioned hypothesis.
The possibility exists that BDNF has a central role in the interaction between all the 
phenomena of interest in this study. BDNF has been linked to regulation of mood (Hashi-
moto, Shimizu, & Iyo, 2004) (at least partly via the serotonergic system), stress response 
(Martinowich & Lu, 2008), sleep pressure (Faraguna, Vyazovskiy, Nelson, Tononi, & Cire-
lli, 2008); and finally, its expression is reduced along with age (Zeng et al., 2011).
Introduction
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1.6  The clomipramine (CLI) model of 
 depression (caused by disturbed sleep)
CLI is a tricyclic antidepressant. It is known to dramatically reduce REM sleep (REMS) 
in neonatal rats (Mirmiran, van de Poll, Corner, van Oyen, & Bour, 1981). The sup-
pression of REMS, at neonatal age, by CLI treatment, results in an infested depressive-
like behaviour at adult age. The signs of depressive-like behaviour include: increased 
alcohol intake, decreased aggression, motor hyperactivity in a stressful situation, in-
creased immobility in “behavioural despair” test and anhedonia in form of decreased 
sexual activity, sucrose preference and intracranial self-stimulation (Feng & Ma, 2002; 
Vogel, Neill, Hagler, Kors, & Hartley, 1990). The animals also show abnormalities in 
sleep that resemble the disturbed REMS pattern observed in human depression (Vo-
gel, Neill, Kors, & Hagler, 1990). Earlier studies have addressed the effect of CLI on 
gene expression using a candidate gene approach (Cassano, Hidalgo, Burgos, Adris, & 
Argibay, 2006; Feng, Guan, Yang, & Fang, 2003; Hansen & Mikkelsen, 1998) but a sys-
tematic survey at the whole-genome level has not been previously performed.
1.7  Basal forebrain (BF) – Sleep and Mood
The BF has been implicated in the regulation of both NREM (Porkka-Heiskanen et al., 
1997) and REM sleep; or more precisely; the cholinergic BF neurons have been shown 
to contribute to generation of theta rhythm (Lee, Hassani, Alonso, & Jones, 2005), pre-
sumably a result of an increased cholinergic activity in the BF (Vazquez & Baghdoy-
an, 2001); whereas glutamatergic activity in the BF has been related to sleep pressure 
(Wigren et al., 2007). Furthermore, the cholinergic cells of BF degenerate in Alzhei-
mer’s disease patients (Teipel et al., 2005; Vogels et al., 1990), who also frequently suf-
fer both from problems in sleep and depressive disorder (Catania et al., 2009; Forstl 
et al., 1992). The anxiolytic effects of benzodiazepines have been ascribed to a mecha-
nism of action where benzodiazepines inhibit the forebrain control system for wake-
fulness (Kajimura et al., 2004), thereby ascertaining the position of BF in both mood 
and sleep regulation.
1.8 Frontal cortex (FCX) – Sleep and Mood
The FCX is mediating normal sleep physiology, dreaming and sleep-deprivation phe-
nomena. During non-REM (NREM) sleep, the FCX exerts the highest voltage and the 
slowest brain waves compared to other cortical regions. The differences between the 
self-awareness experienced in waking and its diminution in dreaming can be explained 
by deactivation of the dorsolateral prefrontal cortex during REM sleep. This deactiva-
tion has been proposed to result from a direct inhibition of the dorsolateral prefron-
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tal cortical neurons by an enhanced release of acetylcholine during REM sleep (Mu-
zur, Pace-Schott, & Hobson, 2002). The FCX has, in several studies, been described as 
a central area involved in the development of depression. Volumetric studies have re-
vealed a reduction of grey matter in FCX amongst depressed patients (Drevets et al., 
1997; Nugent et al., 2006; Rajkowska, 1997). Also within the field of neuroimaging, 
changes in the activation intensity of FCX have been detected in depressed individuals 
during different emotion-related tasks (Murray, Wise, & Drevets, 2011).
1.9 Hippocampus (HIP) – Sleep and Mood
The HIP is another brain area actively involved in sleep and in the handling of mem-
ories and emotions (Walker, 2009). Changes in hippocampal volume have been ob-
served in major depressive disorder (MDD) (Lorenzetti, Allen, Fornito, & Yucel, 2009).
The recent discovery that depressed patients show abnormal hippocampal theta activ-
ity (Cornwell et al., 2010), further contributes to the spatial conception of mood disor-
ders. This regulation of hippocampal theta activity is under the influence of GABAer-
gic neurons (Xu, Datta, Wu, & Alreja, 2004).
 
1.10 Hypothalamus (HYP) – Sleep and Mood
The importance of the hypothalamic region in relation to sleep regulation (Economo, 
1930) had already been discovered at the beginning of the 20th century. The HYP con-
sists of a large number of nuclei, many of which are involved in sleep regulation. The 
HYP partakes in both homeostatic and circadian regulation of sleep, as well as in allos-
teric alterations of sleep (Saper, Scammell, & Lu, 2005). A decrease in hypothalamic vol-
ume can be observed in several affective disorders (Schindler et al., 2012) and as the HYP 
is part of the hypothalamic-pituitary-adrenal (HPA) axis, it is also thereby an important 
regulator of sleep, stress response and mood on a system level (Mormede et al., 2011).
1.11 Connections between Basal forebrain-  
 Hippocampus-Frontal cortex 
 (BF-HIP-FCX)
Connections between the BF, FCX and HIP have been identified and some of these 
connections have been associated with regulation of mood or sleep. According to the 
hypothesis of this study (II), the mood alterations observed in the CLI model would 
be caused by gene expressional changes in these tissues and disruptions of the con-
nections between them.
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1.11.1 Basal Forebrain-Frontal cortex (BF-FCX)
The cells of the BF project widely to the cortex and the limbic system (Porkka-Heis-
kanen et al., 1997; Zaborszky, Pang, Somogyi, Nadasdy, & Kallo, 1999). Through wide-
spread projections to the cerebral cortex, including dense projections to the FCX, the 
BF plays important and diverse roles in the modulation of cortical activity in associa-
tion with different behavioural states (Everitt & Robbins, 1997; Henny & Jones, 2008; 
Sarter, Bruno, & Givens, 2003; Weinberger, 2003). These projections are glutamater-
gic, GABAergic and cholinergic, thus all contributing to the diverse manner in which 
the BF influences cortical activity (Henny & Jones, 2008).
1.11.2  Hippocampus-Frontal cortex (HIP-FCX)
The HIP presents projections to the FCX and some of the projections seem to be re-
ciprocal (Goldman-Rakic, Selemon, & Schwartz, 1984). These projections play an im-
portant role in anxiety disorders, as shown by mice models for anxiety research (Adhi-
kari, Topiwala, & Gordon, 2010).
1.11.3  Basal forebrain-Hippocampus (BF-HIP)
Neuronal projections between the BF and HIP exist, and although less dense and less 
well studied, compared to the BF and HIP projections to the FCX, they have been 
shown to be involved in the generation of theta rhythm (Xu et al., 2004).
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2  Aims of the study
The interplay between stress, mood and sleep is well known in all cultures and 
throughout history. Nevertheless, very little is known about the interplay on a molec-
ular level. The ambitious aim of this study was to unravel these mechanisms. When 
feasible, the research was conducted on a genome-wide scale without a priori desig-
nated genes, pathways or cell-types. The candidate gene based studies on SLC6A and 
BDNF were performed due to financial and methodological restrictions..
Some of the approaches turned out failures, whereas some, discussed here, were 
successful and contribute to the constantly growing amount of information about 
this intricate interplay.
Aim 1. Using the rodent clomipramine model of depression we aimed at identifying 
changes in expression of genes and genetic networks in four brain areas of rat pups 
(I, II) and adult animals (III) that are targeted by the treatment and could thus me-
diate the harmful effects of the treatment on the regulation of sleep, emotions and 
plasticity (II).
Aim 2. In order to clarify the interplay between different brain areas in response to 
clomipramine treatment we aimed at identifying pathways and networks that span 
two or more tissues.(II).
Aim 3. In human white blood cells, identify epigenetic changes in the promoter of a 
serotonin transporter gene, (a gene closely related to regulation of mood/emotions), 
in relation to stressful environment (workstress)(IV).
Aim 4. Identify age-related changes in neuronal plasticity and slow-wave sleep as re-
sponse to sleep restriction (V).
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3  Material and methods
3.1  Animals and treatments
3.1.1  Ethical issues
All animal procedures were approved by the University of Helsinki Ethical Committee 
for Animal Experiments and performed according to applicable legislation (European 
Communities Council Directive of 24 November 1986, 86/609/EC). All efforts were 
made to minimize the number of animals used and their suffering.
3.1.2  Animals and treatments – the clomipramine (CLI)  
 model (I, II, III)
The animals (Wistar Hannover rats, Harlan Laboratories, Horst, The Netherlands) 
were treated with bidaily subcutaneous injections (9 am and 7 pm) of 20mg/kg clomi-
pramine (Sigma-Aldrich, St. Louis, MO, USA) from post-natal day 5 to 21. The con-
trol group was treated with 0.9 % saline (Baxter Oy, Vantaa, Finland). The animals 
were sacrificed by cervical dislocation. 
Number, age and sex of the animals used in the different studies: (I) For expres-
sion analysis: Six CLI treated (3 males, 3 females) and seven (3 males, 4 females) 
controls were sacrificed at the age of 3 weeks (on the day after the last treatment) 
and the BF dissected for extraction of RNA and further analysis with the Affyme-
trix Rat 230.2 chip and TaqMan Realtime RT-PCR. (II) For expression analysis: Six 
CLI treated (3 males, 3 females) and six (3 males, 3 females) controls were sacri-
ficed at the age of 3 weeks and the BF, FCX and HIP were dissected for RNA extrac-
tion. For sleep recordings: 12 male animals underwent the same experimental con-
ditions (6 CLI-treated and 6 controls) and were used for sleep recording at the age 
of 3 months. For sucrose preference test: an additional 26 animals, all males (12 CLI, 
14 SAL), were used (at the age of 3 months) for the sucrose preference test. (III) For 
expression analysis: Six CLI treated animals and five controls (all females) were sac-
rificed at the age of 3 months and their HYP dissected for extraction of RNA and 
further analysis with the Affymetrix Rat 230.2 chip and TaqMan Realtime RT-PCR.
3.1.3  Animals and treatments – the effect of ageing on  
 sleep (V)
Three age groups of male Hannover Wistar rats were used in the experiment: young 
(Y) (3-4 months; 388 ± 11 g; n = 35), middle-aged (M) (12-14 months; 744 ± 25 g; n = 
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28), and old (O) (23-25 months; 698 ± 29 g; n = 27). The animals were housed on a 12 
h light/dark cycle (lights on at 8:30 A.M.) at constant temperature (+22 ± 1°C). Food 
and water were provided ad libitum.
3.2 Human subjects (IV)
Clinical data were obtained from a Finnish cohort comprised of female health care 
professionals, mainly nurses, midwives and nursing assistants. 422 individuals were 
recruited from a total of 5615 health care professionals that were part of a Finnish 
Public Sector Study (Kivimaki et al., 2007). This group represents the entire person-
nel of 21 Finnish public hospitals. These subjects were classified into lowest and high-
est quartile on work stress as in Karasek’s model (Karasek, 1998) in which high work 
stress is implicated by high demands and low control, while low stress is defined by 
low demands and high control. Inclusion criteria was age between 30-60, mother 
tongue Finnish, BMI under 35, at least 3 years of work experience in the same ward 
and no greater than 6 months of absenteeism from work during the past 3 years. Nine-
ty-nine participants took part in laboratory measurements. All laboratory assessments 
were performed blind to ward work stress status.
Exclusion criteria for the current study were use of medication affecting cogni-
tive functions, use of hormonal medication, heavy smoking (reported daily smoking 
for at least 10 consecutive years) and high alcohol intake (4 or more doses of alcohol 
over 4 times a week). After exclusion criteria, a total of 67 subjects were selected for 
analysis. Peripheral blood samples were obtained from well-rested individuals. Writ-
ten consent was obtained from all participants. A total of 49 subjects (73%) were bi-
sulphite sequenced and included in the final analysis for this study. A detailed flow 
chart for sample selection is provided in Figure S1 of Supporting Information (I).
3.3 Dissections (I, II, III, V)
The tissues were dissected according to The rat brain in stereotaxic coordinates by 
Paxinos and Watson (Paxinos & Watson, 1986). All the dissections were performed by 
hand on fresh tissue on ice.
The BF and FCX were dissected bilaterally while the HIP was dissected unilat-
erally, thereby quickly getting samples of suitable size, making the RNA extraction 
more precise and saving time to reduce the RNA degradation. We aimed at the BF 
cholinergic region including the horizontal limb of the diagonal band of Broca, sub-
stantia innominata and magnocellular preoptic area (anterior = - 0.3; lateral = 2.0; 
vertical = 9). The dissected area was 2 mm thick. The frontal cortex was dissected 
from the part of the brain rostral to bregma -0.3 and included the cortex above cor-
pus callosum and external capsule. The hippocampus and hypothalamus were dis-
sected en block.
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3.4 DNA / RNA / Protein - extractions 
 (I, II, III, V)
(I, II, III) The dissected brain tissues were immediately homogenized in cold RLT Plus 
buffer (Qiagen, Hilden, Germany) with added β-mercaptoethanol using a handheld 
rotor homogenizer and a syringe fitted with a 0.9 mm needle and stored at -80°C. RNA 
was extracted using the AllPrep DNA/RNA Mini kit by Qiagen following the supplied 
protocol. DnaseI treatment of the RNA fraction was carried out using the Rnase-Free 
Dnase Set by Qiagen as a precaution against gDNA contamination of the RNA. Both 
fractions were measured for purity and concentration using the Nanodrop ND-1000 
spectrophotometer (NanoDrop Technologies, Rockland, DE, USA).
(V) The dissected brain tissues were stored in the AllProtect Tissue Reagent sta-
bilizer (Qiagen, Hilden, Germany) at -80°C. Half of the tissue was used for measur-
ing BDNF mRNA expression and the other half for measuring BDNF protein expres-
sion. Tissue for BDNF mRNA expression was homogenized in Qiazol Lysis Reagent 
using a bead mill Tissue Lyser (Qiagen). Chloroform was added and the homoge-
nates were centrifuged to enhance separation of the RNA phase. After the homog-
enization RNA was immediately extracted using RNA Later Lipid Mini Tissue Kit 
according to the protocol supplied (Qiagen). DNase treatment of the RNA fraction 
was carried out using the RNAse-Free DNase Set (Qiagen) as a precaution against 
genomic DNA contamination. The RNA fraction was measured for purity and con-
centration using the Nanodrop ND-1000 spectrophotometer (NanoDrop Technol-
ogies, Rockland, DE, USA). Due to technical problems RNA was not obtained from 
the middle-aged rats deprived for 3 hours.
The tissues for the BDNF protein expression analysis, were homogenized in 1:5 
ratio buffer (50mM Tris–HCl, pH 7.5, 130mM NaCl, 1mM EDTA, 1mM EGTA, 1% 
(v/v) TX100, 2.5mM sodium pyrophosphate, 1mM betaglyserol-2-phosphate and 
1mM phenylmethylsulphonyl fluoride, including inhibitor cocktails (Sigma–Al-
drich Co., St. Louis, MO)) and centrifuged for 30 min at 6 °C. The protein homoge-
nates were stored in -80 °C. 
3.5  Gene expression
3.5.1  Gene expression analysis – array (I, II, III)
After extraction RNA quality was further tested with the Agilent Bioanalyzer 2100 
(Agilent Technologies, Palo Alto, CA, USA). The arrays were performed according to 
the Affymetrix standard protocol (Affymetrix, Santa Clara, CA, USA). In brief, 2 µg 
of RNA was used to prepare biotinylated cRNA using the Affymetrix GeneChip One-
cycle target labelling kit after which 15µg of the cRNA was fragmentated and hybrid-
ized to the Affymetrix Rat 230.2 chip. Hybridization, staining and washing were per-
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formed using the Affymetrix Fluidics Station 450 and Hybridization Oven 640 under 
standard conditions and according to the Affymetrix protocol.
(I) For the array data analysis we used the commercially available software Gene-
Spring GX 7 (Agilent Technologies, Santa Clara, CA).  The analysis was executed as 
follows: after a GC-RMA preprocessing of the raw data the signals were normalized 
to the median per gene and the Affymetrix control probes were subtracted. To en-
sure that the analysis would pick up both differentially expressed genes and ON/OFF 
genes, a filtering on flags using the CHP files so that flags had to be present or margin-
al in at least 4 of 6 in the CLI samples and / or 5 of 7 in the control samples was done. 
All genes that had normalized data between 0.666 and 1.5 in 11 of 13 samples were fil-
tered out and a fold change (FC) limit of 1.3 was set to describe our criteria on differ-
ential expression. The p-value (Wilcoxon-Mann-Whitney test) limit was set to 0.05. 
To take into account the multiple testing performed and the false discovery rate, the 
q-values (Storey & Tibshirani, 2003) were calculated by bootstrapping, for each gene. 
For this we used the QVALUE package running in R environment. As input we used 
all the 956 genes left before any statistical testing.
(II) In the array analysis we used the free CHIPSTER v1.4.0 software provided by CSC 
(IT Center for Science, Helsinki, Finland). The expression data were analyzed by com-
paring the expression levels of single genes in the CLI treated animals with the con-
trols, separately in the three different tissues. The data analysis was executed as fol-
lows: after a Gene Chip Robust Multichip Averaging (GC-RMA) pre-processing of 
the raw data the samples were linked to the phenodata and the Affymetrix control 
probes were subtracted. To ensure that the analysis would pick up both differentially 
expressed genes and ON/OFF genes, a filtering on flags using the probe set informa-
tion chip files generated by Affymetrix (CHP files) was done so that genes that pre-
sented two or more Absent flags in both groups were filtered out. The average fold 
change (FC) limit was set at 1.5 to describe our criteria for differential expression. The 
significance for the differentially expressed genes was calculated by students T-test 
and a limit was set to 0.05.
To take into account the multiple testing performed and the false discovery 
rate, the q-values (Storey & Tibshirani, 2003) were calculated by bootstrapping, for 
each gene. For this we used the QVALUE package running in R environment. As in-
put we used all the genes left before any statistical testing (BF=655, FCX=195 and 
HIP=611).
(III) The expression levels of individual genes of CLI-treated animals and controls 
were compared using GeneSpring GX 9.0.5 software (Agilent Technologies, Santa 
Clara, CA, USA). Array raw intensity values were normalized and converted to ex-
pression summaries by GC Robust Multichip.
Average (GC-RMA), the signals were then normalized to the median per gene 
and the Affymetrix control probe sets (57) were removed. To ensure that the anal-
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ysis would pick up both differentially expressed genes and ON/OFF genes, a filter-
ing on flags using the CHP files (so that flags had to be present or marginal in 67% 
of the samples in any 1 of 2 treatment conditions) was performed. The obtained list 
of genes was further filtered by fold-change (FC) so that genes up- or down-regulat-
ed with less than 1.5 FC were removed. Differential expression was tested by Mann-
Whitney unpaired test, and significance was set at p<0.05.
3.5.2  Gene expression analysis – Realtime RT-PCR   
 (I,III,V)
TaqMan real-time quantitative reverse transcriptase PCR was performed using ABI 
PRISM 7900 Thermal Cycler and TaqMan gene expression assays (Applied Biosys-
tems, Foster City, CA, USA). 1 μg of RNA was used as starting material for the reverse 
transcription using the Advantage-RT for PCR kit (Clontech Carlsbad, CA, USA). cD-
NA samples were amplified using a TaqMan Universal PCR MasterMix and the com-
mercial gene expression assays with primers and probes. The program was set on 50°C 
2min - 95°C 1min and 50 cycles of repeating 95°C for 15 seconds and 60°C for 1min. 
All samples and assays were run in triplicates. Expression values were normalized to 
Cyclophilin A (PPIA(Rn00690933_m1), which was used as endogenous control. The 
endogenous control was chosen based on its steady expression throughout the array 
experiment. Standard curves were prepared accordingly to be able to calculate the 
changes in gene expression using the comparative delta (CT) method. A Students T-
test was performed to estimate the statistical significance of the detected changes in 
expression between the two groups.
(I) TaqMan probes (Applied Biosystems) for: DNMT2(Rn01765153_m1), 
SOX6(Rn01507719_m1), PDE4D(Rn00566798_m1), ACATN(Rn00573865_m1), 
FGFR2(Rn01269940_m1), IGF2(Rn00580426_m1) and PPIA(Rn00690933_m1).
The endogenous control was chosen by examining the expression profiles and 
intensities (on the arrays) of 30 genes commonly used as endogenous controls in or-
der to find the best endogenous control for this specific experiment. Cyclophilin A 
was present at a suitable intensity and showed very little variation between samples.
(III) TaqMan probes (Applied Biosystems) for: TTR (Rn00562124_m1), DLG3 
(Rn01419350_m1), DNAJC5 (Rn00577363_m1), SNX10 (Rn01763032_m1) and 
PPIA (Rn00690933_m1) as endogenous control.
(V) TaqMan probes (Applied Biosystems) for: BDNF(Rn02531967_s1) and 
PPIA(Rn00690933_m1) as endogenous control.
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3.5.3  Gene expression analysis – protein (V)
Acidified brain homogenates were analyzed for BDNF expression using sandwich 
ELISA, as described in (Karpova et al., 2010). The protein expression was calculated 
using standard curves and normalized to total protein. The total protein concentra-
tion was measured from the protein homogenates, using NanoDrop ND-1000 spec-
trophotometer (NanoDrop Technologies, Wilmington, DE, USA) and used for data 
normalization.
3.6  Quantitative analysis of site-specific DNA  
 methylation (IV,N/A)
(IV) We isolated DNA from peripheral blood leucocytes using QIAGEN Autopure 
(Qiagen). CpG methylation status of the CpG-rich region in the SLC6A4 gene pro-
moter was investigated by bisulphite sequencing (Frommer et al., 1992). The region 
of SLC6A4 that was included in the analysis has been previously shown to be differ-
entially methylated in infants exposed to prenatal maternal depressed mood (Devlin, 
Brain, Austin, & Oberlander, 2010).
500ng of genomic DNA from leucocytes was treated with sodium bisulphite us-
ing the EZ DNA Methylation-Gold Kit (Zymoresearch) following the manufactur-
er’s protocol. The region of interest was amplified by standard PCR from bisulfite-
treated DNA using AmpliTaq Gold Hot Start Polymerase (Applied Biosystems) 
based on previously published primers (Devlin et al., 2010) with slight modifica-
tions in region coverage as a necessity to produce good quality sequence with di-
rect sequencing. SLC6A4F: gtattgttaggttttaggaagaaagagaga and SLC6A4R: aaaaatc-
ctaactttcctrctctttaactt.
Overhanging tails in the 5’ end were designed for both forward and reverse 
primers that match with common T7 (taatacgactcactataggg) and T3 (attaaccctcac-
taaaggga) sequencing primers respectively. Cycling conditions were 95°C for 11 
minutes followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C 
for 40 seconds with a final extension of 10 minutes at 72°C. PCR products were ver-
ified randomly on a 2% agarose gel (GellyPhor, Euroclone). The remaining PCR 
product was purified using the Quickstep 2 PCR Purification Kit (Edge Bio). 
Cycle sequencing was performed with the BigDye Terminator version 3.1 Cy-
cle Sequencing Kit (Applied Biosystems) using T7 and T3 sequencing primers. Se-
quencing was performed by capillary sequencing (Finnish Institute for Molecular 
Medicine). A similar method has been previously described (Lewin, Schmitt, Ador-
jan, Hildmann, & Piepenbrock, 2004).
Methylation percentage at each CpG site was quantified manually using the Se-
quence Scanner version 1.0 (Applied Biosystems) by two independent examiners 
blind to the sample identification codes. The peak heights of C versus the combined 
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heights of C + T peaks (C/C+T) at each CpG locus were calculated as a percentage 
(Lewin et al., 2004). The five CpG locations were 28 563 120 (CpG5), 28 563 109 
(CpG4), 28 563 107 (CpG3), 28 563 102 (CpG2), and 28 563 090 (CpG1) as per hg19 
assembly of the UCSC Genome Browser. The success rate for DNA amplification 
and bisulfite sequencing was 73% (49/67). 
Correlations between methylation levels in all five CpG residues were calculat-
ed using the Pearson’s Correlation. Structural equation measurement model was an-
alyzed in order to test the hypothesis that these correlations could be explained by a 
single latent factor. Principal component factor analysis was used to obtain the sin-
gle sum methylation value METsum. Statistical significance (2-tailed p<0.05) be-
tween methylation of each five CpG residue and work stress was assessed using the 
Student’s T-test. Associations between work stress, MBI-GS, METsum and 5-HT-
TLPR were assessed by analysis of covariance (ANCOVA). In the initial multivaria-
ble model, we analyzed the main effects of 6 variables and 15 variables in the inter-
action model. Non-significant variables were then systematically eliminated using a 
stepwise backward elimination method until all significant variables were left in the 
final model.    The tools used in all analysis were SPSS Statistics 18, PLINK (http://
pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007) and SAS analytics (SAS 
Institute, Cary, NC). 
(N/A) Unpublished work (related to manuscript I): The DNA fraction from BF, ex-
tracted simultaneously with the RNA from the clomipramine model (3.4) was sub-
ject to DNA methylation analysis of the BDNF, NTRK2, IGFII and ACATN promot-
er areas. The protocol was developed from previously published ones (Lewin et al., 
2004) and a predecessor of the one described above and thus similar with the excep-
tion of primer design and method for estimating the degree of methylation. The prim-
ers were designed using MethPrimer (Li & Dahiya, 2002). The estimation of the de-
gree of methylation was done by comparing to a dilution curve of in vitro methylated 
(using SssI) DNA.
3.7  Genotyping (IV)
5-HTTLPR genotype was assayed in two stages. Amplification of 5-HTTLPR was 
carried out using PCR using the primers HTTLPR_F (gttgccgctctgaatgccag) and 
HTTLPR_R (ggataatgggggttgcaggg) that amplify either the long, L allele (280 bp 
product) or the short, S allele (236 bp product). The reaction was run in a total vol-
ume of 20 μl containing 60 ng of genomic DNA, 500 nM primers, 10 mM dNTP, 2.5 
mM MgCl2 and 0.7U Dynazyme II Hotstart polymerase (Finnzymes). Thermocycling 
conditions were 94°C initial denaturing for 10 min followed by 35 cycles of the fol-
lowing: denaturing at 94°C for 15 s, annealing at 65°C for 20 s and extension at 72°C 
for 25 s. This was followed by a final extension at 72°C for 10 min. 5 μl of PCR prod-
uct was then mixed with 8 units of Msp I restriction enzyme (Pharmacia Biotech) in 
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One-Phor-All assay buffer. The reaction mixture was then incubated at 37°C for 16 
hours followed by 20 min at 65°C. 5-HTTLPR genotypes were assessed on a 2% gel. 
Associations between work stress, MBI-GS, METsum and 5-HTTLPR were assessed 
by analysis of covariance (ANCOVA). In the initial multivariable model, we analyzed 
the main effects of 6 variables and 15 variables in the interaction model. Non-signifi-
cant variables were then systematically eliminated using a stepwise backward elimina-
tion method until all significant variables were left in the final model.    The tools used 
in all analysis were SPSS Statistics 18, PLINK (http://pngu.mgh.harvard.edu/purcell/
plink/) (Purcell et al., 2007) and SAS analytics (SAS Institute, Cary, NC).
3.8 Pathway analysis (I, II, III)
In the pathway analysis we studied groups of genes, functionally related to each oth-
er, rather than single genes. In this approach, an aggregate score (based on the abso-
lute FC of each probeset) for genes in specific categories was computed and the signif-
icance of the aggregated change in each pathway was estimated by random sampling, 
using a custom made program (similar to (Pietilainen et al., 2008; Pontynen et al., 
2008; von Schantz et al., 2008)). An input list consisting of the total number of probes 
on the Affymetrix Rat chip excluding the control probes was used (31,042 target se-
quences). Rattus Norvegicus core (50.34t in manuscripts I & III, 53.34u in manuscript 
II) and gene ontology database (50 in manuscripts I & III, 53 in manuscript II) by En-
sembl (Hubbard et al., 2005) was the source of choice for retrieving the gene ontology 
information for the probes. By utilizing the directed topology of the Gene Ontology 
(GO) tree by traversing all available routes to the root of the GO tree, all encountered 
vertexes were added as GO annotations for the given gene. The non-parametric iter-
ative cumulative hypergeometric distribution was calculated and further tested using 
100,000 permutations:
 
where j=absolute rank of the probeset/gene; k=rank of the probeset /gene amongst all 
the members of the pathway; t=total number of probeset /genes in the pathway; and 
n=total number of probeset/genes in the experiment. The objective is to find the op-
timum p-value for a set of genes which belongs to the same annotated GO collection 
(maximal regulation for the pathway).
By using input lists sorted by absolute FC values this analysis was designed to 
search for the most differentially expressed pathways and not up- or down- regulat-
ed pathways separately (as common praxis).
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(II) Inter-tissue pathway analysis
To identify differentially expressed pathways that possibly span more than one tissue, 
using the same pathway analysis method as described above, we combined the exper-
imental data from the three different tissue studies. We made an input list by combin-
ing the total probe set data from the BF, FCX and HIP, and sorting the list according 
to descending absolute FC (Figure 1). To allow the same gene to appear in the input 
list from more than one tissue, but to avoid artifacts because of larger genes being de-
tected by multiple probes, we first discarded all but the highest ranking probe for each 
gene in the input list from the separate tissues, but allowed for duplicates later in the 
combined analysis.
The output was divided into two: pathways consisting of 50 to 200 genes and 
pathways of less than 50 genes. In this way the larger pathways, of an often more gen-
eral nature, were separated from the smaller, more specific pathways.
                    
Figure 1. On the left: Example of a pathway that spans three tissues. The arrows each repre-
sent the complete gene list from an array experiment in one tissue, sorted according to de-
scending absolute Fold Change (FC) of treated vs. controls. The pathway consists of genes A, 
B, C and D. Genes A, B and C are connected and within the same pathway, although they are 
detected (presenting a high FC) in three different tissues.
On the right: By combining the gene lists from the three different array experi-
ments and sorting the combined list according to descending absolute Fold Change 
(FC) one can easily, by using any regular program for pathway analysis, detect differ-
entially expressed pathways that span one, two, or all three tissues. (Figure used un-
der permission from Journal of Neurogenetics (II))
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3.9  Inter-tissue network analysis (II)
To find important interactors and visualize the gene networks involved between 
the three brain areas (See Figure 2 for a simplified view), the STITCH 2.0 software 
(Kuhn et al., 2010; Kuhn, von Mering, Campillos, Jensen, & Bork, 2008) was used. 
The input list consisted of a list combined from the most differentially expressed 
genes in BF, HIP and FCX (Supplementary Tables 1a, 1b and 1c (in II)). The maxi-
mum number of interactors was set to twelve and all prediction methods and data-
bases were activated. The confidence level (score) for edges to qualify was set to 0 in 
order not to emphasize well studied genes and molecules. The nodes were manually 
categorized (by colouring) as either belonging to BF expressed, HIP expressed, FCX 
expressed or interactor.
   
Figure 2. Example of a gene network consisting of four genes A, B, C and D detected in three 
different tissues. The interactor X, that connects the four genes, has no defined physical loca-
tion. (Figure used under permission from Journal of Neurogenetics (I)) 
3.10 Promoter analysis (I)
The most outstanding genes from the array analysis were subject to a promoter analysis. 
Using Ensmart (Biomart) a list of the mouse orthologues was created (Durinck 
et al., 2005). Sequences of +/- 2000 bp from the transcription start site were analyzed 
for enrichment of binding sites for vertebrate transcription factors using oPOSSUM 
(www.cisreg.ca/oPOSSUM). Only non – coding areas with 70 % conservation to hu-
man were used and the findings were compared to a random background.
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3.11 Search for over-represented biological   
 motifs (II)
The DAVID functional annotation tool (Huang da, Sherman, & Lempicki, 2009) was 
used to search for over-represented biological motifs according to gene ontologies. 
As input we used a list combined from the most differentially expressed genes in BF, 
HIP and FCX (Supplementary Tables 1a, 1b and 1c (in II)). FAT GO terms (for each, 
Biological Process, Cellular Component and Molecular function) were used in or-
der to eliminate the largest gene ontologies, without sacrifying relevant information. 
The calculation was made using the whole Affymetrix Rat 230.2 chip as background 
and the p-value cut-off was set at 0.05.
3.12  Behavioural testing - Sucrose preference  
 test (II)
The animals (n=26: 12 CLI and 14 SAL) were housed individually throughout the test 
session. During the 48h training session, starting at 19:00, each animal was present-
ed with 2 bottles in the cage: one containing 1% sucrose solution and the other con-
taining standard drinking water (Bhagya, Srikumar, Raju, & Shankaranarayana Rao, 
2008). The volume of water and sucrose water intake was measured every 24h and bot-
tle positions were exchanged during this period. After an 18h period of food and wa-
ter deprivation (to increase the efficacy of the test) a 2h test session was conducted 
(starting at 13:00). The amount of liquid remaining in each bottle was measured at the 
end of the testing period. The sucrose preference score was expressed as a percentage 
of total fluid intake (sucrose preference = sucrose water consumed / total liquid con-
sumed x 100), and the data were normalized to animal body weights. During the test 
period all animals were given a full bottle (250 ml) of both water and sucrose solution. 
The test was performed at the age of 3 months (all males, to exclude sex differences).
3.13  Sleep deprivation (SD) (V)
To keep the animals awake and to evoke active waking and exploratory behaviour, 
novel objects (e.g. wooden blocks, Styrofoam objects and stretchable strings) were 
introduced to the cages. Whenever an animal appeared behaviourally sleepy, or slow 
waves were visible in the EEG, a new object was introduced or the cages were gently 
tapped. This method is referred to as sleep deprivation by gentle handling (Franken, 
Dijk, Tobler, & Borbely, 1991).
Animals were deprived of sleep for either 3 or 6 hours (from 1 P.M. to 4 P.M. 
or from 10 A.M. to 4 P.M., respectively). This experiment was repeated twice to al-
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low for recording of EEG recovery sleep after the first SD, with a minimum 48 hours 
between the experiments. The animals were then sacrificed by decapitation imme-
diately after the end of the deprivation. An age-matched control group was left un-
disturbed and sacrificed at the same circadian time point.  All animals in the EEG 
group were deprived of sleep for 6 hours (from 10 A.M. to 4 P.M.). 
3.14  Sleep recordings and analysis (II, V)
(II) Six animals treated with CLI and 6 treated with saline were recorded for sleep 
at the age of 3 months. The rats (all males, to exclude sex differences) were implant-
ed under general anaesthesia (3mg/kg i.p. diapam, 0.5 mg/kg domitor and 50 mg/kg 
ketalar i.p.) with electrodes for recording of electroencephalogram (EEG) and elec-
tromyogram (EMG). Two EEG electrodes were screwed in frontoparietal positions 
(2mm rostral and 2 mm lateral to bregma; 4 mm rostral and 1 mm lateral to lamb-
da); two silver EMG electrodes were inserted into neck muscles. After one week of 
recovery rats were connected to counterbalanced recording leads for 48-hour adap-
tation before the actual 48-hour baseline EEG recording took place. The EEG/EMG 
signals were amplified (Bioamplifier AC-916, CWE, Inc., Ardmore, PA USA) and 
sampled at 104 Hz. EEG data were digitally high-pass filtered (0.75 Hz) for removing 
low-frequency artefacts and divided into 5-s epochs which were manually scored for 
REM sleep using the program Spike 2 (version 5.11; Cambridge Electronic Devices, 
Cambridge, UK). Total REM sleep amount, REM sleep fragmentation, and average 
length of REM sleep bouts were calculated for each hour during the 24 hours of re-
cording. To calculate REM sleep fragmentation and the length of bouts, only REM 
epochs with duration starting from 10s, were considered.
(V) A group of animals (Y, n=8; M, n=7; O, n=8) were implanted with chronic epi-
dural EEG electrodes and dorsal nuchal EMG electrodes under anaesthesia (2.5 mg/
kg, i.p. diazepam; 0.4 mg/kg, i.p. medetomidine; 60 mg/kg, i.p. ketamine) for study-
ing vigilance states and EEG activity. The bipolar screw EEG electrodes were placed 
contralaterally to the skull (2 mm caudal and 2 mm lateral from bregma; 2 mm ros-
tral and 1 mm lateral from lambda) and fixed to the skull with acrylic dental ce-
ment. After surgery, rats were single-housed in Plexiglas boxes and allowed to re-
cover for 1 - 2.5 weeks. After connecting the EEG/EMG cables (Plastics1, Va, USA) 
the animals were allowed to adapt for one more week, after which a stable 24 hour 
baseline recording was obtained prior to the experiments. The EEG/EMG signal was 
amplified (gain 10,000) and filtered (HP 0.3 Hz, LP 100 Hz) using a 16 channel am-
plifier (Model 3500, A-M Systems, Carlsborg, WA, US). The signal was digitized at 
277 Hz with an A/D converter (unit 1401, Cambridge Electronics, Cambridge, UK), 
monitored on-line during the experiments and stored on a standard computer using 
Spike2 software (Cambridge Electronics, Cambridge, UK).
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The multiple sleep latency test (MSLT), using continuous EEG/EMG recording, 
adapted from McKenna et al. (McKenna et al., 2008), was performed after a 6-hour 
baseline period, from 10 AM to 4 PM, during which spontaneous sleep-wake behav-
iour was allowed to occur, or after 6 hours of SD by gentle handling, from 10 Am to 4 
PM. The MSLT consisted of short (5 min) periods of wakefulness induced by gentle 
handling, followed by longer (25 min) periods during which the animals were free 
to sleep. This procedure was repeated every 30 min for 3 hours (from 4 PM to 7 PM) 
and was designed to minimize the amount of sleep lost due to the testing procedure.
The EEG/EMG recordings from the last baseline day and from the two 6-hour 
SD days were scored in 5 second epochs for wake, NREM sleep and REM sleep with 
an automated scoring program (Rytkonen, Zitting, & Porkka-Heiskanen, 2011). 
Sleep scoring was done for the baseline day, the MSLT-baseline day, and the MSLT 
sleep deprivation day. Baseline NREM delta power (0.75-4 Hz) was calculated from 
the 24-hour baseline and normalized to total power from the same period. Recovery 
sleep NREM delta power (0.75-4 Hz) was calculated from the recovery sleep follow-
ing SD, altogether for 16 hours (4 PM to 8 AM), and normalized to baseline values.
For power spectral analysis the first 25 minutes, from the beginning of the re-
covery sleep period following 6-hour SD, was manually checked to exclude artefacts 
and to correct for vigilance state errors. The NREM power spectra was generated 
in the Spike2 program (Cambridge Electronics) using fast Fourier transform (512 
Hanning window; 0.4 Hz resolution) within a frequency range of 0.75–35 Hz, aver-
aged over the time period investigated, and normalized to total power of the same 
recording period. The amount of recovery NREM sleep delta (0.75-4 Hz), was used 
as a measure of sleep intensity.
3.15  Work stress, burnout and depression   
 assessment (IV)
From the baseline 5615 female health care professionals, potential subjects (n=422) 
were chosen to respond to the Karasek’s Job Content Questionnaire (JCQ). This was 
based on two consecutive questionnaires of work stress in 2004 and 2008. Three 
questions assessed job demand and 9 questions assessed job control. Responses to 
all questions were given on a 5-point scale (completely agree, somewhat agree, not 
agree/neither disagree, somewhat disagree, completely disagree). The division into 
high and low work stress groups was based first on grouping the wards with at least 5 
respondents according to the mean score of survey responses to the job demand and 
job control scales at ward level, using median split to identify high stress (high de-
mands and low control) and low stress (low demands and high control) wards. Using 
these cut-off points, the nurses from the wards were identified, who belonged to the 
same high and low stress groups also based on their individual mean score values of 
job demands and job control. Finally, to increase contrast between the comparison 
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groups, nurses who belonged to the quartile with least stress in the high stress group 
and most stress in the low stress group were excluded. 
To assess burnout in our study sample, each subject took the Maslach Burnout 
Inventory General Survey (MBI-GS). MBI-GS is a modified version of the original 
MBI to measure levels of burnout in occupations that involve working closely with 
people (Schaufeli, Leiter, Maslach, & Jackson, 1996). The survey covers all the three 
components of burnout: exhaustion (EX), cynicism (CY), and professional effica-
cy (PE). Subjects scoring higher than 1.5 in the MBI-GS were considered to have at 
least moderate burnout.
Depression was measured using the Beck Depression Inventory (BDI) (A. T. 
Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). The questionnaire is widely used 
to screen depression in clinical practice and in community samples (Aaron T. Beck, 
Steer, & Carbin, 1988). Subjects scoring between 10 and 18 were considered to have 
mild depression while scores of 19 to 29 represent moderate to severe depression. 
Associations between work stress, MBI-GS, METsum and 5-HTTLPR were assessed 
by analysis of covariance (ANCOVA). In the initial multivariable model, we ana-
lyzed the main effects of 6 variables and 15 variables in the interaction model. Non-
significant variables were then systematically eliminated using a stepwise backward 
elimination method until all significant variables were left in the final model.    The 
tools used in all analysis were SPSS Statistics 18, PLINK (http://pngu.mgh.harvard.
edu/purcell/plink/) (Purcell et al., 2007) and SAS analytics (SAS Institute, Cary, NC).
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4  Results
4.1  Findings in the clomipramine (CLI) model
4.1.1  Sleep recordings and Sucrose preference test (II)
The interest in the clomipramine model to this study is its effect on both sleep and 
mood. According to the proposed mechanism, the neonatal treatment would affect 
the sleep of the young animals, with the outcome of depressive-like behaviour and 
sleep pattern at adult age (Feng & Ma, 2002; Vogel, Neill, Kors et al., 1990). The su-
crose preference is used to detect signs of anhedonia, which in turn is a symptom of 
depression (Willner & Mitchell, 2002). The sleep recordings and testing for sucrose 
preference were performed for two concomitant reasons: 1) to further validate the 
model itself in order to verify that the neonatal treatment with clomipramine has a 
permanent effect on both sleep and mood, and 2) to ensure that the introduction of 
the model to our laboratory has been successful.
The sleep recordings of the three months old animals show that the CLI treated 
animals present permanent changes in sleep architecture. As compared to the con-
trol animals they present an increase in overall REM sleep during the first hour of 
darkness (20.30-21.30) and REM sleep fragmentation between 19.30-20.30 (p=0.03) 
and 03.30-04.30 (p=0.048) (Figure 3). The CLI treated animals also exhibit shorter 
REM bouts during the four night hours (p=0.029) as well as towards the end (19.30-
20.30) of the light period (p=0.014).
The sucrose preference testing show the CLI treated animals to have a reduced 
sucrose preference (56.62 +/-9.57%) compared to the control animals (78.83 +/-
5.52%), as measured in percentage of sucrose solution consumed out of total fluid 
consumed (p=0.048) (Figure 4).
Additionally, by measuring the animals during both the sleep recordings and 
the sucrose preference testing, we detected a decreased bodyweight in the animals 
from the CLI group. A t-test showed (p=0.028) that the average adult bodyweight of 
the CLI treated animals (307.5 ± 8.6 g) was lower than in the control group of CLI 
treated animals (332.6 ± 5.5 g) during the sleep recordings, whereas the respective 
weights during the sucrose consumption testing were 370.3 ± 9.9 g for the CLI group 
and  415.9 ± 10.1 g for the control group (p=0.004).
Not only do these findings indicate that permanent changes occur due to neo-
natal CLI treatment, but they also display the reproducibility of the clomipramine 
model.
Results
37Molecular mechanisms of sleep and mood Research 100 ∙ 2013
National Institute for Health and Welfare
 
 30 
  
                          
Figure 4. Sucrose preference of three months old rats that have undergone clomipramine vs. saline treatment in 
early infancy. The sucrose preference score is expressed as a percentage of total fluid intake (sucrose preference = 
sucrose water consumed / total liquid consumed x 100), and the data were normalized to animal body weights. 
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Figure 3. REM sleep fragmentation during 24h in rats treated with clomipramine (CLI). The animals were treated 
with daily injections of CLI (n = 6) or saline (Sal) (n = 6) for 2 weeks in their early infancy. The sleep was recorded 
at the age of three months. The CLI animals had increased REM sleep fragmentation at 19.30-20.30 (p=0.03) and 
03.30-04.30 (p=0.048). Thus, early administration of CLI leads to permanent disturbance of sleep in the animals. * 
p<0.05 (Figure used under permission from Journal of Neurogenetics (II)) 
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4.1.2  Differentially expressed inter-tissual pathways and 
 networks between basal forebrain (BF), 
 hippocampus (HIP) and frontal cortex (FCX) (II)
The disorders of interest arise due to dysfunction of several brain areas and are not 
attributed to any exact brain area or cell type. The inter-tissual analyses were de-
signed to detect possible imbalance in networks and pathways that span two or three 
different brain areas. The results reveal pathways and networks possibly involved in 
the communication between these areas as well as in the phenomena of interest. The 
brain areas included in this study were chosen for their previously reported function 
and interconnectivity.
By the inter-tissue network approach we managed to visualize the involved net-
works on a molecular level (Figure 5). Furthermore, this analysis revealed: 1) the most 
interconnected genes of the primary expression analysis, and 2) predicted function-
al partners, not detected in the primary expression analysis, that are either genes/gene 
products or other molecules of natural or synthetic origin (Table 1).
1. Transforming protein RhoA (Rhoa), RAS-associated protein Rab-3A (Ra-
b3a) and Carbonic anhydrase IV (Ca4).
2. Gene products: Fibroblast growth factor (Fgf1), Vascular endothelial growth 
factor A (Vegfa), Rabphilin-3A (Rph3a). Other molecules: serotonin, sero-
tonin agonists 5-carboxamidotryptamine, 1-(2,5-dimethoxy-4-iodophenyl)-
2-aminopropane and the serotonin derivative 5-methoxytryptamine, the 
maleate salt of methylergonovine methylergometrine, the ergot alkaloid er-
gotamine, lysergic acid diethylamide (LSD), JNK (c-Jun N-terminal kinase) 
inhibitor SP600125 and manganese Mn(II).
In overall, the most highly interconnected molecules were: Vegfa, Rhoa, seroto-
nin and Mn(II).
The inter-tissue pathway analysis revealed pathways or gene ontology groups that 
are affected by the CLI treatment. To separate more specific pathways from general 
ones, pathways of 2) less than 50 genes (Table 2b) were examined separately from the 
larger pathways 1) consisting of between 50 and 200 genes (Table 2a).
1. The  most significantly changed pathways within the Biological Process 
– category (BP) were those of nerve-nerve synaptic transmission (opti-
mal p=8,84E-10, permuted p=1,00E-06) and the regulation of transmis-
sion of nerve impulse (optimal p=9,35E-11, permuted p=1,00E-06), where-
as the Molecular Function – category (MF) presented the most significant 
changes in pathways related to translation activity (starting from optimal 
p=6,55E-08, permuted p=6,00E-06) and small conjugating protein-specif-
ic protease activity, or more precisely, ubiquitin activity (starting from op-
timal p=3,40E-10, permuted p=1,00E-06). Spatially, the largest changes, 
as explained by the Cellular Component – category (CC) seem to be tak-
ing place in the axons (optimal p<10E-38, permuted p=1,00E-06) and the 
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melanosomes/pigment granules (optimal p=1,35E-07, permuted p=8,00E-
06/1,1E-05).
2. Apart from the pathways for astrocyte development and glutamate signal-
ling, the separation of smaller pathways also revealed pathways directly re-
lated to behaviour such as startle response, conditioned taste aversion and 
visual learning.
The strongest contributors to any of the significantly changed pathways were the 
precursors for Pro-melanine concentrating hormone (Pmch), Transthyretin (Ttr) and 
Orexin (Hcrt).
Figure 5. A network view of differentially expressed genes in the basal forebrain, frontal 
cortex and hippocampus. Circular spheres denote genes/proteins, whereas the pillshaped 
spheres denote small non-RNA dependent molecules. Colour scheme: red = differentially 
expressed in the basal forebrain, yellowish =  differentially expressed in the frontal cortex, 
green = differentially expressed in hippocampus, blue = interactor. Genes that are differen-
tially expressed in two tissues are two-coloured. Refer to Table 1 for scores and details of the 
interactors. (Figure used under permission from  Journal of Neurogenetics (II))
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Table 1. Predicted functional partners (interactors) derived from the network analysis. Re-
fer to Figure 5 for a complete view of the networks involved. (Table adapted from Journal of 
Neurogenetics (II))
Predicted functional partners Score
Rph3a Rabphilin-3A (Exophilin-1); Protein transport. Probably in-
volved with Ras-related protein Rab-3A in synaptic vesicle 
traffic and/or synaptic vesicle fusion. Could play a role in 
neurotransmitter release by regulating membrane flow in 
the nerve terminal.
0.999
1-(2,5-dimethoxy-4 
iodophenyl)-2-ami-
nopropane
Hallucinogen; Serotonin agonist (321.2 g/mol) 0.999
5-methoxytryptamine 5-methoxytryptamine; Serotonin derivative proposed as 
potentiator for hypnotics and sedatives. (190.2 g/mol)
0.999
ergotamine A naturally occurring ergot alkaloid with vasoconstrictor 
and analgesic property. Ergotamine selectively binds and 
activates serotonin (5-HT) 1D receptors located on intracra-
nial blood vessels, including those on arterio-venous anas-
tomoses, thereby resulting in vasoconstriction and reducing 
the blood flow in cerebral arteries that may lead to relie-
ve of vascular headaches. This agent also selectively binds 
to alpha-adrenergic receptors, thereby stimulating vascu-
lar smooth muscle and causing vasoconstriction in both 
arteries and veins, which also contributes to the relief of 
headaches. Furthermore, the activation of 5-HT1D recep-
tors on sensory nerve endings of the trigeminal system re-
sults in the inhibition of pro-inflammatory neuropeptide 
release.
0.999
methylergometrine The maleate salt of methylergonovine, a semi-synthetic er-
got alkaloid with vasoconstrictive and uterotonic effects. 
Methylergonovine stimulates serotoninergic and dopa-
minergic receptors as well as inhibits the release of en-
dothelial-derived relaxation factor. This results in arterial 
vasoconstriction and increased uterine smooth muscle cont-
ractions.
0.999
serotonin Serotonin agent (176.2 g/mol) 0.999
SP600125 JNK (c-Jun N-terminal kinase) inhibitor (220.2 g/mol) 0.999
Fgf1 Heparin-binding growth factor 1 precursor (HBGF-1) (Aci-
dic fibroblast growth factor) (aFGF); The heparin-binding 
growth factors are angiogenic agents in vivo and are po-
tent mitogens for a variety of cell types in vitro. There are 
differences in the tissue distribution and concentration of 
these 2 growth factors.
0.999
Vegfa Vascular endothelial growth factor A precursor (VEGF-A) 
(Vascular permeability factor) (VPF); Growth factor active in 
angiogenesis, vasculogenesis and endothelial cell growth. 
Induces endothelial cell proliferation, promotes cell migra-
tion, inhibits apoptosis and induces permeabilization of 
blood vessels. Binds to the VEGFR1/Flt-1 and VEGFR2/Kdr 
receptors, heparan sulfate and heparin (By similarity). May 
play a role in increasing vascular permeability during lacta-
tion, when increased transport of molecules from the blood 
is required for efficient milk protein synthesis.
0.998
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5-carboxamidotryp-
tamine
Serotonin agonist (203.2 g/mol) 0.998
lysergic acid 
diethylamide
A substance that yields hydrogen ions or protons in aqueo-
us solutions; a substance capable of accepting a pair of elec-
trons for the formation of a coordinate covalent bond; a 
substance whose hydrogen can be replaced by metals or 
basic radicals, or which react with bases to form salts and 
water.
0.998
Mn(II) An element with atomic symbol Mn, atomic number 25. 
(54.9 g/mol)
0.998
Table 1. (continues)
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Table 2a. Differentially expressed inter-tissue pathways, spanning the basal forebrain, frontal cortex and 
hippocampus. Pathway size: 51-200 genes (Table adapted from Journal of Neurogenetics (II)).
Table2a Inter-tissue Pathways  51-200 genes
Cellular Component
ID Pathway     Opt. 
p-value
Permuted Total # 
genes
Top # 
of genes
p<0.0025 in 
individual  
tissues
p-value in pathway in pathway BF FCX HIP
GO:0030424 axon <10E-38 <1,00E-06 184 72
GO:0030426 growth cone      1,42E-08 4,00E-06 68 38
GO:0030427 site of polarized
growth      
1,42E-08 4,00E-06 68 38
GO:0008021 synaptic vesicle      2,93E-08 5,00E-06 131 26
GO:0048770 pigment granule      1,35E-07 8,00E-06 140 137
GO:0042470 melanosome      1,35E-07 1,10E-05 140 137
GO:0030136 clathrin-coated vesicle  1,64E-07 2,20E-05 175 115
GO:0030425 dendrite      2,39E-07 2,50E-05 180 37
GO:0031252 leading edge      3,86E-07 2,60E-05 141 124
GO:0005769 early endosome      7,42E-07 2,60E-05 60 49
GO:0030118 clathrin coat      7,87E-07 2,70E-05 67 58
GO:0019717 synaptosome      4,65E-07 3,70E-05 120 108
GO:0005770 late endosome      1,91E-06 6,10E-05 62 46
GO:0030135 coated vesicle      9,34E-07 6,30E-05 199 126
GO:0014069 postsynaptic density      3,10E-06 9,90E-05 65 15
GO:0016528 sarcoplasm      3,52E-06 0,0001 58 24
GO:0048475 coated membrane      1,75E-06 0,000105 117 93    
GO:0030117 membrane coat      1,75E-06 0,000114 117 93    
GO:0030662 coated vesicle 
membrane      
4,05E-06 0,000138 68 66    
Molecular Function
ID Pathway     Opt. 
p-value
Permuted Total# 
genes
Top# 
of genes
p<0.0025 in 
individual  
tissues
p-value in pathway in pathway BF FCX HIP
GO:0019783 small conjugating 
protein-specific 
protease activity      
3,40E-10 <1,00E-06 101 86
GO:0004843 ubiquitin-specific 
protease activity      
1,02E-09 2,00E-06 98 94
GO:0004221 ubiquitin thiolesterase 
activity      
3,84E-09 2,00E-06 93 89
GO:0004842 ubiquitin-protein 
ligase activity      
4,29E-09 4,00E-06 157 111
GO:0003743 translation initiation 
factor activity      
6,55E-08 6,00E-06 105 95
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GO:0004812 aminoacyl-tRNA ligase 
activity      
1,57E-07 1,30E-05 139 128
GO:0005543 phospholipid binding   1,05E-07 1,50E-05 166 121
GO:0045182 translation regulator 
activity      
1,86E-07 1,50E-05 142 127
GO:0016876 ligase activ. forming 
aminoacyl-tRNA & 
related comp.
1,57E-07 1,60E-05 139 128
GO:0008135 translation factor 
activity, nucleic acid 
binding      
1,86E-07 1,80E-05 142 127
GO:0016875 ligase activity, forming 
carbon-oxygen bonds   
1,57E-07 2,00E-05 139 128
GO:0008080 N-acetyltransferase 
activity      
7,22E-07 2,60E-05 76 59
GO:0016247 channel regulator 
activity      
9,05E-07 3,00E-05 63 31
GO:0015457 auxiliary transport 
protein activity      
9,05E-07 3,20E-05 63 31
GO:0016407 acetyltransferase 
activity      
1,96E-06 8,70E-05 90 67
GO:0005516 calmodulin binding      3,02E-06 0,000187 189 83
GO:0016836 hydro-lyase activity      6,99E-06 0,000241 75 7
Biological Process
ID Pathway     Opt. 
p-value
Permuted Total # 
genes
Top# 
of genes
p<0.0025 in 
individual  
tissues
p-value in pathway in pathway BF FCX HIP
GO:0051969 regulation of transmis-
sion of nerve impulse      
9,35E-11 <1,00E-06 194 25
GO:0007270 nerve-nerve synaptic 
transmission      
8,84E-10 <1,00E-06 116 32
GO:0051129 negative regulation of 
cellular component 
organization      
1,95E-09 <1,00E-06 119 90
GO:0006418 tRNA aminoacylation 
for protein translation  
3,13E-09 <1,00E-06 129 122
GO:0048489 synaptic vesicle 
transport      
5,47E-09 <1,00E-06 60 17
GO:0050804 regulation of synaptic 
transmission      
5,78E-10 2,00E-06 191 24
GO:0007218 neuropeptide 
signaling pathway      
7,63E-10 2,00E-06 126 39
GO:0043039 tRNA aminoacylation      3,13E-09 2,00E-06 129 122
GO:0043038 amino acid activation   3,13E-09 2,00E-06 129 122
GO:0001505 regulation of neuro-
transmitter levels      
3,63E-10 3,00E-06 151 30
Table 2a. (continues)
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GO:0035249 synaptic transmission, 
glutamatergic      
3,34E-08 3,00E-06 65 21
GO:0008380 RNA splicing      4,35E-08 8,00E-06 165 143
GO:0007611 learning or memory      1,19E-07 1,10E-05 156 20
GO:0007269 neurotransmitter 
secretion      
9,24E-08 1,30E-05 100 92
GO:0022618 ribonucleoprotein 
complex assembly      
3,07E-07 1,70E-05 110 98
GO:0042417 dopamine 
metabolic process      
4,58E-07 1,70E-05 58 10
GO:0006584 catecholamine 
metabolic process      
5,48E-07 1,80E-05 75 9
GO:0051494 Neg. reg. of cytoskele-
ton organization 
and biogenesis      
1,37E-06 3,10E-05 54 43
GO:0031646 positive regulation of 
neurological system 
process      
8,83E-07 3,80E-05 70 11
GO:0033043 regulation of 
organelle 
organization and
biogenesis      
6,49E-07 4,10E-05 165 116
GO:0010639 Neg. reg. of 
organelle 
organization and 
biogenesis      
1,37E-06 4,10E-05 54 43
GO:0043087 regulation of GTPase 
activity      
6,49E-07 4,90E-05 117 82
GO:0032269 Neg. reg. of cellular 
protein metabolic 
process      
8,60E-07 5,30E-05 140 97
GO:0016567 protein ubiquitination  8,14E-07 6,20E-05 124 85
GO:0055114 oxidation reduction      2,04E-06 6,70E-05 60 59
GO:0032535 regulation of cellular 
component size      
1,67E-06 7,40E-05 78 44
GO:0051493 regulation of cyto-
skeleton organization 
and biogenesis      
1,68E-06 8,90E-05 162 113
GO:0051248 negative regulation of 
protein metabolic 
process      
1,36E-06 9,00E-05 146 100
GO:0031109 microtubule 
polymerization or 
depolymerization      
3,17E-06 0,000106 71 53
GO:0050767 regulation of 
neurogenesis      
1,69E-06 0,000119 171 114
GO:0022900 electron 
transport chain      
4,35E-06 0,000123 57 56
GO:0022904 respiratory electron 
transport chain      
4,35E-06 0,000125 57 56
Table 2a. (continues)
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GO:0031110 Reg. of microtubule 
polymerization / 
depolymerization      
4,62E-06 0,000126 65 49
GO:0032446 protein modification 
by small protein 
conjugation      
1,94E-06 0,000131 133 107
GO:0006413 translational initiation  4,19E-06 0,000155 86 64
GO:0050770 regulation of 
axonogenesis      
3,32E-06 0,000157 86 63
GO:0007631 feeding behavior      4,22E-06 0,00019 104 12
GO:0007613 memory      6,66E-06 0,000191 61 10
GO:0007411 axon guidance      3,73E-06 0,000196 166 71
GO:0006403 RNA localization      4,40E-06 0,000203 91 82
Table 2a. (continues)
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Table 2b. Differentially expressed inter-tissue pathways, spanning the basal forebrain, frontal cortex and 
hippocampus. Pathway size: 0-50 genes (Table adapted from Journal of Neurogenetics (II)).
Table2b Inter-tissue Pathways  0-50 genes
Cellular Component
ID          Pathway     Opt.  
p-value
Permuted Total # 
genes
Top# 
of genes
p<0.0025 in 
individual 
tissues
p-value in pathway in pathway BF FCX HIP
GO:0030665 clathrin coated vesicle 
membrane      
2,32E-07 8,00E-06 49 45
GO:0060053 neurofilament 
cytoskeleton      
1,50E-06 1,60E-05 19 19
GO:0005883 neurofilament      3,37E-06 3,10E-05 16 16
GO:0031091 platelet alpha granule   7,04E-06 3,10E-05 6 2
GO:0042734 presynaptic membrane 2,80E-06 6,50E-05 47 14
Molecular Function
ID          Pathway     Opt. 
p-value
Permuted Total # 
genes
Top# 
of genes
p<0.0025 in 
individual 
tissues
p-value in pathway in pathway BF FCX HIP
GO:0004089 carbonate dehydratase 
activity      
4,02E-08 3,00E-06 36 7
GO:0017067 tyrosine-ester sulfo-
transferase activity      
7,70E-06 1,20E-05 3 3
GO:0016151 nickel ion binding      2,82E-06 2,40E-05 9 3
GO:0017034 Rap guanyl-nucleotide 
exchange factor 
activity      
1,94E-05 4,90E-05 3 3
GO:0070052 collagen V binding      2,82E-05 5,50E-05 3 3
GO:0004827 proline-tRNA ligase 
activity      
1,48E-05 7,30E-05 6 5
GO:0015066 alpha-amylase 
inhibitor activity      
4,94E-05 0,00011 3 3
GO:0015459 potassium channel 
regulator activity      
1,11E-05 0,000112 12 4
GO:0015349 thyroid hormone 
transmembrane 
transporter activity      
2,10E-05 0,000117 6 2
GO:0004691 cAMP-dependent 
protein kinase activity   
3,13E-05 0,000128 6 5
GO:0004712 protein 
serine/threonine/
tyrosine kinase 
activity      
2,00E-05 0,000194 12 11
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Biological Process
ID          Pathway     Opt. 
p-value
Permuted Total # ge-
nes
Top# of ge-
nes
p<0.0025 in 
individual 
tissues
p-value in pathway in pathway BF FCX HIP
GO:0007215 glutamate signaling 
pathway      
1,33E-07 2,00E-06 24 13
GO:0016079 synaptic vesicle 
exocytosis      
6,35E-08 4,00E-06 34 12
GO:0007598 blood coagulation, 
extrinsic pathway      
1,41E-06 6,00E-06 3 2
GO:0046655 folic acid metabolic 
process      
2,62E-06 6,00E-06 3 2
GO:0051346 negative regulation of 
hydrolase activity      
5,50E-07 7,00E-06 25 15
GO:0042706 eye photoreceptor cell 
fate commitment      
3,08E-05 2,60E-05 2 2
GO:0051966 regulation of synaptic 
transmission, glutama-
tergic      
2,19E-06 3,30E-05 40 14
GO:0046552 photoreceptor cell fate 
commitment      
3,08E-05 3,40E-05 2 2
GO:0051968 pos. regulation of 
synaptic transmission, 
glutamatergic      
5,67E-06 4,60E-05 14 5
GO:0016338 calcium-independent 
cell-cell adhesion      
4,85E-06 5,70E-05 18 6
GO:0006433 prolyl-tRNA aminoacy-
lation      
1,48E-05 6,20E-05 6 5
GO:0030514 negative regulation of 
BMP signaling pathway 
5,90E-06 7,70E-05 19 2
GO:0014002 astrocyte development 8,37E-06 9,40E-05 15 5
GO:0001661 conditioned taste 
aversion      
9,32E-06 9,50E-05 12 6
GO:0008542 visual learning      4,16E-06 0,0001 49 12
GO:0016188 synaptic vesicle 
maturation      
1,30E-05 0,000101 9 4
GO:0001964 startle response      7,11E-06 0,00012 33 7
GO:0007632 visual behavior      5,22E-06 0,000124 50 12
GO:0051261 protein depolymerization 6,67E-06 0,000147 50 45
GO:0017157 regulation of exocytosis 8,14E-06 0,000171 38 31
GO:0007217 tachykinin signaling 
pathway      
3,67E-05 0,000172 6 5
GO:0030510 regulation of BMP sig-
naling pathway      
1,30E-05 0,000215 28 2
GO:0060052 neurofilament cytoske-
leton organization & 
biogenesis      
1,81E-05 0,000229 21 16    
Table 2b. (continues)
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4.1.3  Differentially expressed pathways within the basal  
 forebrain (BF) (I) and the hypothalamus (HYP) (III)
The BF and HYP are important structures related to the regulation of both sleep and 
mood. Detecting pathways, within these tissues, that are in inequilibrium would ex-
plain the function of these areas in the clomipramine model and thereby possibly 
elucidate the involvement of these brain areas in the regulation of sleep and mood.
Within the BF (Table 2 in (I)) we detect changes in pathways or gene ontolo-
gy groups related to the cellular component – category (CC) of the synapse (optimal 
p=1.7E-07, permuted p=0.00001) and the biological process – category (BP) of syn-
aptic transmission (optimal p=9.3E-09, permuted p=0.00001), regulation of neuro-
transmitter levels (optimal p=3.92E-07, permuted p=0.00002) and the more specif-
ic pathway for serotonin receptor phospholipase C activation (optimal p=4.89E-05, 
permuted p=0.00004). The most differentially expressed pathway within the molec-
ular function – category (MF) is the gamma-aminobutyric acid (GABA) signalling 
pathway (optimal p=7.6E-05, permuted p=0.00099), emphasizing the role of BF in 
GABAergic neurotransmission.
The pathways presenting the statistically most significant changes in the HYP 
(Table 1 in (III)) are of a more general nature. The changes are located to (CC) syn-
aptic vesicles (optimal p=7.81E-07, permuted p=3.00E-05) and related to (BP) mac-
romolecular (RNA and protein) metabolism (starting from optimal p=3.74E-11 and 
permuted p=1.00E-05).  Molecular functions (MF) such as GTPase activity (optimal 
p=7.07E-08, permuted p=1.00E-05) and protein ligase activity (starting from opti-
mal p=2.23E-07 and permuted p=1.00E-05) are altered. Nevertheless, also more pre-
cise (MF) pathways such as extracellular-glycine-gated chloride channel activity and 
GABA-A receptor activity are detected at reasonable level of statistical significance. 
Unfortunately the HYP had to be excluded from the inter-tissue analysis as the sam-
ples consist of 3-month old females, and can therefore not be normalized together 
with the samples from BF, FCX and HIP of three week old animals.
4.1.4 Promoter analysis of the differentially expressed  
 genes in basal forebrain (BF) (I)
By analysing the promoter areas of the most differentially expressed genes within 
the BF (Table 1 in (I)), for an enrichment of common regulatory motifs, important 
transcription factor binding sites (TFBS) were detected. The over-represented TFBS, 
and their respective transcription factors (TF) could be responsible for the chang-
es in gene expression within the tissue. The number of analysed genes was reduced 
to 48 due to insufficient sequence data and the criterias set for the promoter areas.
In the analysis five TFBS qualified at p<0.0025 (Table 3). The top TFBS was found 
in 23 of the investigated promoters, and binds the cAMP response element-binding 
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protein 1 (CREB1) (see Discussion for a background on this molecule). This CREB1 
binding site is over-represented amongst the promoters at a Z-score of 9.113, generat-
ing a Fisher score of p=0.000059.
Table 3. Search for enriched binding sites for transcription factors (TF; TFBS) among differen-
tially expressed genes in basal forebrain of animals treated with clomipramine (n=6) as com-
pared to those treated with saline (n=7) at the age of 3 weeks. (Table adapted from European 
Journal of Neuroscience (I))
TF = Transcription factor, TFBS = Transcription factor binding site,IC = The information content 
or specificity of this TFBS profile’s position weight matrix, Z–Score = The likelihood that the 
number of TFBS nucleotides detected for the included target genes is significant as compared 
with the number of TFBS nucleotides detected for the background set. Z-score is expressed in 
units of magnitude of the standard deviation, Fisher Score = The probability that the num-
ber of hits vs. non-hits for the included target genes could have occurred by random chance 
based on the hits vs. non-hits for the background set (table adapted from (I) European Jour-
nal of Neuroscience )
4.1.5 DNA methylation analysis of Brain-derived   
 neurotrophic factor (BDNF) , Neurotrophic tyrosine  
 kinase receptor, type 2 (NTRK2), Insulin-like growth  
 factor 2  (IGFII) and Acetyl-Coenzyme A transporter 1  
 (ACATN) promoters in basal forebrain (BF)
The promoters of BDNF, NTRK2, IGFII and ACATN show no significant difference 
in DNA methylation, between the two groups (clomipramine treated / saline treat-
ed), at any of the CpG sites investigated (unpublished data). This implies that neither 
gene is under transcriptional regulation by DNA methylation in the BF.
TF TF Class
Background 
genes
Target ge-
nes
Background 
TFBS
Target TFBS
Z-
score
Fisher 
score
Hits
Non-
hits
Hits
Non-
hits
Hits Rate Hits Rate
CREB1 bZIP 3892 11258 23 19 5673 0,0055 33 0,0086 9,113 5,90E-05
Ddit3-
Cebpa
bZIP 2749 12401 16 26 3888 0,0038 19 0,005 4,214 1,90E-03
MIZF ZN-
FINGER,
C2H2
1298 13852 10 32 1531 0,0012 11 0,0024 7,048 2,47E-03
TLX1-
NFIC
HOMEO/
CAAT
435 14715 5 37 456 0,0005 5 0,0015 9,461 7,01E-03
Pdx1 HOMEO 9899 5251 35 7 54092 0,0261 242 0,0317 7,404 8,41E-03
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4.2 Age dependent changes in sleep (V)
The NREM sleep, slow wave activity (SWA) and the sleep latency were analyzed in 
relation to age, and considered as measures of sleep need, recovery sleep respective-
ly sleep pressure. Reduced effects according to age, after sleep deprivation, would in-
dicate an age dependent decrease in sleep pressure buildup during restricted sleep. 
The reason for analysing the expression of BDNF together with the sleep data is 
to investigate the relation between plasticity genes and sleep pressure.
4.2.1 Sleep latency (SL)
The normal SL for the three age groups was tested after a baseline period. An age re-
lated reduction in SL can be observed between the young and the old animals (Two-
Way Repeated Measures ANOVA, followed by Holm-Sidak post hoc test, p<0.05) 
(Figure 6). After a 6h sleep deprivation (SD) all age groups present a reduction in SL. 
The magnitude of the reduction in SL is similar in all age groups, with the exception 
of the last hour, when the old animals present a significantly higher SL, as compared 
to the two other groups (Figure 6b).
 
 
Figure 6a. Mean latency (aver-
aged per hour) to non-rapid eye 
movement (NREM) sleep after a 
baseline period during which spon-
taneous sleep-wake behaviour oc-
curred. The old rats have a sig-
nificant decrease in sleep latency 
compared to young rats in the sec-
ond hour after onset of test (Figure 
adapted from (V)). 
Figure 6b. Latency to non-rapid eye 
movement (NREM) sleep after 6 h 
sleep deprivation. Old rats have a sig-
nificant increase in sleep latency com-
pared to young in the third hour after 
the onset of test (REC= start of recov-
ery sleep). Number of animals: young, 
n=7; middle-aged; n=6, old, n=9. Sig-
nificances: between age-group signif-
icance denoted with an asterisk (*); 
near significant denoted with a plus 
(+) (Figure adapted from (V)).
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 Figure 7. Mean latency (averaged per hour) to non-rapid eye movement (NREM) sleep after a 
baseline period during which spontaneous sleep-wake behaviour occurred and after 6 h sleep 
deprivation in young (A), middle-aged (B) and old (C) rats. Both young and middle rats exhibited 
significantly decreased sleep latencies following sleep deprivation (as compared to baseline val-
ues) during the whole 3 hour test period, while the old rats the sleep latency was significantly de-
creased only during the first hour. Number of animals: see Figure . Significances: inside age group 
significance denoted with an asterisk (*) (Figure adapted from (V)).
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The SL after SD compared to the SL after the baseline period, for each animal, 
show that the latency stays lower during the whole test (3 hours) only in the young 
rats (Figure 7A), whereas the aged animals have a significant decrease in SL only 
during the first two hours (middle-aged rats, Figure 7B) or the first hour (old rats, 
Figure 7C) of testing.
The average number of interventions during the whole 6 hour SD in the dif-
ferent age groups was: Young, 31 ± 4; Middle-aged, 53 ± 7; Old 111 ± 13 (One-Way 
ANOVA, p =< 0.001 between all groups) (Figure 8).
 
Figure 8. Number of interventions during the 6 hour sleep deprivation (SD). Old rats had signifi-
cantly more interventions during SD than either young or middle-aged rats (Figure adapted from 
(V)).
4.2.2 Non-REM (NREM) sleep
During the baseline period the young animals present higher NREM delta (0.75-4 
HZ) values compared to both old and middle-aged rats during the first 6 hours of 
lights on (8.30 AM to 2.30 PM). Also between hours 7 and 13 (2.30 PM to 9.30 PM) 
the young rats have higher delta values compared to the old animals, but no differ-
ence can be detected between the young and the middle aged, nor between the mid-
dle aged and the old (Two-Way Repeated Measures ANOVA followed by Holm-
Sidak post hoc test, p<0.05) (Figure 9A).
During the first three hours of recovery sleep a rise in delta power (0.75-4 HZ) in 
the young animals, as compared to both the middle-aged and the old, can be observed 
after normalization to baseline levels. Between hours 7 and 13 (2.30 PM to 9.30 PM) 
this rise is only significant when compared to the old animals (Two-Way Repeated 
Measures ANOVA followed by Holm-Sidak post hoc test, p<0.05) (Figure 9b).
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Figure 9a. Baseline NREM delta power (0.75-4 Hz) expressed as percentage of total power. The young rats have 
significantly higher NREM delta values compared to both old and middle-aged rats during the first 6 hours of lights on 
(8.30 AM to 2.30 PM), and significantly higher NREM delta values compared to old rats between hours 7 and 13 
(2.30 PM to 9.30 PM) (Two-Way Repeated Measures ANOVA followed by Holm-Sidak post hoc test, p<0.05) (Figure 
adapted from (V)). 
Figure 9b. Recovery NREM delta power (0.75-4 Hz) normalized to baseline values. The young rats have significantly 
higher NREM delta values compared to both old and middle-aged rats during the first 3 hours of recovery sleep (4 
PM to 7 PM), and significantly higher NREM delta values compared to old rats between hours 7 and 13 (2.30 PM to 
9.30 PM) (Two-Way Repeated Measures ANOVA followed by Holm-Sidak post hoc test, p<0.05) (Figure adapted 
from (V)). 
The lower frequencies in the NREM power spectra (0.75-35 Hz) from the first 
25 min of recovery sleep are elevated in all age groups (Figure 10). 
Differences between the age groups in the lower frequencies can also be 
observed. Young rats have more NREM power in the frequencies from 0.75 
Hz to 3.55 Hz compared to both middle-aged and old rats. The young rats 
also  present more NREM power in the frequencies from 3.55 Hz to 4.75 Hz, 
but only when compared to the old group (Two-Way Repeated Measures 
ANOVA followed by Holm-Sidak post hoc test, p<0.05), thus covering the 
whole delta frequency (0.75-4 Hz) spectrum (Figure 10). 
 
Figure 10. NREM EEG power (0.75-35 Hz) during the first 25 minutes of recovery sleep after sleep deprivation 
(before first MSLT activation), normalized to baseline total power. Significant differences between aged groups were 
found in the 0.75 Hz to 4.75 Hz frequencies with young rats showing consistently higher power in these frequencies 
(Two-Way Repeated Measures ANOVA followed by Holm-Sidak post hoc test, p<0.05) (Figure adapted from (V)). 
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Figure 9b. Recovery NREM delta power (0.75-4 Hz) normalized to baseline values. The young 
rats have significantly higher NREM delta values compared to both old and middle-aged rats dur-
ing the first 3 hours of recovery sleep (4 PM to 7 PM), and significantly higher NREM delta values 
c mpa ed to old rats betwee hours 7 and 13 (2.30 PM to 9.30 PM) (Two-Way Repeated Measures 
ANOVA followed by Holm-Sidak post hoc test, p<0.05) (Figure adapted from (V)).
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Figure 10. NREM EEG power ( . - 5 Hz) during the first 25 minutes of recovery sle  after 
sleep deprivation (before first MSLT activation), normalized to baseline total power. Significant dif-
ferences between aged groups were found in the 0.75 Hz to 4.75 Hz frequencies with young rats 
showing consistently higher power in these frequencies (Two-Way Repeated Measures ANOVA fol-
lowed by Holm-Sidak post hoc test, p<0.05) (Figure adapted from (V)).
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4.2.3 Response of Brain-derived neurotrophic factor   
 (BDNF) and slow wave activity (SWA) to sleep   
 deprivation (SD)
At the level of mRNA, the expression of BDNF in the cortex is increased in all age 
groups after both 3h and 6h of SD. The magnitude of the increase in BDNF expres-
sion at mRNA level, after SD, is significantly smaller in the aged animals than in the 
young animals (p=0.015) (Figure 11a). These changes correlate positively with SWA 
during the first 25 min of NREM recovery sleep as aged rats have lower BDNF mR-
NA expression and lower SWA and young rats have higher BDNF expression and re-
spectively higher SWA (Pearson’s product moment, p<0.05) (Figure 12).
The concentration of the BDNF protein, during the SD, acts completely differ-
ently. BDNF protein expression is slightly increased during the 3h SD (not statisti-
cally significant) in all age groups, whereas a clear drop in BDNF protein concentra-
tion can be observed in all age groups after the 6h SD (p<0.05, for all) (Figure 11b).
 
Figure 11a. BDNF mRNA expression (fold change) after sleep deprivations (SD). BDNF mRNA ex-
pression increased significantly in all aged groups following either 3 hour or 6 hour SD. (note the 
missing middle-aged 3h SD group, replaced by a white bar depicting the expected value). There 
was a significant difference between the young and aged (middle-aged and old) animals during 
the 3h and 6 SD (One-Way ANOVAs followed by Holm-Sidak post hoc tests, p<0.05, t-test was 
used to compare 6h SD between young and old, p=0.015). Number of animals: young control, 
n=7; young 3hsd, n=6; young 6hsd, n=12; middle-aged ctrl, n=5, middle 3hsd, n=0, middle-aged 
6hsd, n=13; old ctrl n=5, old 3hsd, n=5; old 6hsd, n=5). Significances: inside age group denot-
ed with an asterisk (*); between age groups denoted with a hash (#) (Figure adapted from (V)).
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 Figure 11b. BDNF protein expression decreased following 6 hours of sleep deprivation (6hsd) 
compared to control conditions (ctrl) in all age groups. BDNF expression tended to increase follow-
ing 3 hours of sleep deprivation (3hsd) compared to control conditions (ctrl) in all age groups, but 
this increase did not reach significance. Overall, BDNF expression in young rats significantly dif-
fered from the BDNF expression in middle-age and old rats (Two Way ANOVA followed by Holm-
Sidak post-hoc test, p<0.05. Number of animals: young control, n=13; young 3hsd, n=11; young 
6hsd, n=14; middle-aged ctrl, n=11, middle 3hsd, n=6, middle-aged 6hsd, n=12; old ctrl n=13, old 
3hsd, n=9; old 6hsd, n=5). Significances: inside age group denoted with an asterisk (*); between 
age groups denoted with a hash (#) (Figure adapted from (V)).
 
Figure 12. Significant correlation between cortical BDNF mRNA levels (frontal cortex) and the in-
crease in slow-wave activity (SWA, normalized) during the first 25 minutes of non-rapid eye move-
ment (NREM) sleep. Number of animals: young, n= 7; middle-aged, n=5; old n=5) (Figure adapt-
ed from (V)).
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4.3 The effect of environmental stress on the  
 serotonergic system (IV)
The DNA methylation analysis was performed in order to detect possible differenc-
es in the DNA methylation of the SLC6A4 promoter between the high- and low-
workstress groups. Such differences would suggest a mechanism for the regulation 
of SLC6A4 in relation to work stress. Furthermore, the method used in the analysis 
would also expose the exact locations for the DNA methylation. Through the ques-
tionnaire we wanted to ascertain that high work stress actually correlates with burn-
out and/or depression in the material used. The genotyping of the subjects was per-
formed in order to investigate if either genotype was predisposed to the negative 
effects of workstress. A secondary analysis was performed to detect if differences in 
DNA methylation, between the two genotypes, exist. In case of such differences, the 
relevance of the differences in DNA methylation could fall under dispute.
4.3.1 Self assessed burnout and depression in relation to  
 work stress
According to Karaseks Model (Karasek, 1998), 24 of the subjects (nurses) are catego-
rized to work in a high stress environment and 25 in a low stress environment. Based 
on scores from the Maslach Burnout Index General Survey (MBI-GS), half of the 
subjects (n=12) belonging to the high stress group report at least moderate burnout 
symptoms (MBI-GS scores higher than 1.5), whereas none of the subjects belong-
ing to the low stress group report any symptoms of burnout (MBI-GS scores low-
er than 1.5). The mean score is 1.3(±0.76) for the high stress group and 0.72(±0.49) 
for the low stress group (Table 4). This difference qualifies as statistically significant 
(p=2.3 x 10E-5, t-test).
To detect signs of depression the Beck Depression Index (BDI) was used. In the 
high stress group 12 subjects are rated with mild depression (BDI 10-18) and two 
subjects are rated with moderate to severe depression (BDI >18). In the low stress 
group three subjects rate as mildly depressed, whereas none are rated as moderate-
ly or severely depressed. The mean BDI scores are 8.36(±6.31) and 4.37(±3.36) in 
the high and low stress groups respectively (Table 4). This difference in mean BDI 
scores proved to be statistically significant (p=2x10E-3, t-test), thereby identifying 
the nurses in the high works stress group to be more vulnerable to depression. By 
using categorical variables according to the three assigned categories (0=no depres-
sion, 1=mildly depressed, 2=moderate to severe depression) the t-test p-value is fur-
ther reduced to 2.1x10E-4.
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Table 4. Demographic data of the nurse groups by work stress. (Table adapted from (IV) PLOS ONE)
Work Stress Environment N Age MBI-GS BDI
High work stress 24 49 (± 6.02) 1.33 (±0.760) 8.36 (±6.31)
Low work stress 25 48 (±6.78) 0.723 (±0.487) 4.37 (±3.36)
4.3.2 CpG methylation of the Serotonin transporter 6A4  
 (SLC6A4) promoter
The methylation levels of the SLC6A4 promoter are found to be lower in the high 
work stress group compared to the low work stress group, suggesting that the ac-
tivity of SLC6A4 is regulated by DNA methylation. This finding is consistent for all 
five CpG dinucleotides investigated. The methylation levels of the five CpG sites are; 
CpG1 = 5.5±2.7, CpG2 = 5.9±3.5, CpG3 = 9.8±3.7, CpG4 = 3.7±2.8, CpG5 = 4.2±3.0 
in the high stress group and CpG1 = 13±6.7, CpG2 = 12±5.7, CpG3 = 15±5.4, 
CpG4 = 8.8±4.3, CpG5 = 7.8±3.5 in the low work stress group. A t-test calculation 
show these changes to be highly significant (p=7.10E-06, p=2.50E-05, p=0.000292, 
p=4.37E-06, and p=0.000289 respectively) (Figure 13). As the investigated CpG sites 
are located close together (Figure 14), it is likely that they share a common function 
and that their methylation/demethylation is concerted. This is also the case as all five 
sites are detected in a principal component analysis (PCA). A sum score for methyl-
ation was then calculated by multiplying the values for each individual CpG residue 
by its factorial loading obtained in the first component of PCA. These weighted val-
ues were then summed up to create a weighted sum score, referred to as ”METsum”. 
The mean METsum in the high work stress group is 25.7±10.6 (95% confidence in-
terval 21.2-30.1) and 50.7±21 (95% confidence interval 42.0-59.4) in the low work 
stress group. The mean METsum in the total sample is 38.4±20.8. In order to deter-
mine the effect size between work stress groups, the Cohen’s d for the difference be-
tween the means was calculated (50.7-25.7)/20.8=1.2. The effect size of 1.2 indicates 
that the difference is notable. These results are summarized in Figure 15 and Table 5.
Table 5. METsum in high and low work stress groups and work stress environment as a whole. 
The effect size can be calculated using Cohen’s d, defined as the difference between the two 
means of high and low work stress groups divided by the standard deviation for the complete da-
ta. (Table adapted from (IV) PLOS ONE)
Work stress environment Mean SD Lower 95% CL 
for Mean
Upper 95% CL for 
Mean
High work stress 50.7 21.0 42.0 59.4
Low work stress 25.7 10.6 21.2 30.1
Work stress environment 38.4 20.8 32.5 44.4
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Figure 13. Methylation in the promoter of SLC6A4 at five CpG sites in high (grey) and low 
(white) work stress environments. Coordinates for each residue are 28 563 120 (CpG5), 28 563 
109 (CpG4), 28 563 107 (CpG3), 28 563 102 (CpG2), and 28 563 090 (CpG1) as per hg19 assem-
bly of the UCSC Genome Browser. Differences between work stress environments were significant 
as per t-test (p=7.10E-06, p=2.50E-05, p=0.000292, p=4.37E-06, and p=0.000289 respectively). 
Standard errors are indicated. (Figure used under permission from (IV) PLOS ONE)
Figure 14. Reresentation of the SLC6A4 gene promoter region for bisulfite sequencing analy-
sis. Analyzed CpG sites are in bold and numbered from 1 through 5. Coordinates are based on 
the hg19 assembly of USCS Genome Browser. (Figure used under permission from (IV) PLOS ONE)
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 Figure 15. Distribution of methylation levels in the high and work stress environments. Work 
stress is defined according to Karasek’s Model by the difference between averages of work de-
mand and control. (Figure used under permission from (IV) PLOS ONE) 
A linear regression analysis was performed by analysis of covariance (ANCO-
VA) to assess the association of the calculated METsum (as dependent variable) with 
work stress environment, burnout, work control, work demand, age, and 5-HTTL-
PR (as explanatory variables). When the main effects of all explanatory variables 
are included into the model, only work stress is statistically significant and inde-
pendently (F=5.7; p=0.022) associated with METsum (Table 6). After elimination 
of non-significant effects from the model, both work stress (p<0.0001) and MBI-
GS (p=0.038) are independently associated with the methylation levels and together 
they explain 43% of the variance of METsum (R2=0.43, p<0.0001).
Table 6. Results of the initial main effects model using METsum as dependent variable. (Table 
adapted from (IV) PLOS ONE)
Variable df Type III SS F P
Work stress 1 1480.196769 5.66 0.0221
5-HTTLPR 2 685.987277 1.31 0.2806
MBI-GS 1 695.005206 2.66 0.1108
Control 1 222.192198 0.85 0.3621
Demand 1 0.01083 0 0.9949
Age 1 448.159783 1.71 0.1979
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4.3.3 Effects of the 5-HTTLPR genotype
No significant association between the different genotypes (La/La, La/S and S/S) 
and work stress or burnout is present. The METsum scores show no correlation with 
genotype (Table 7) and after testing the interactions for the genotype and work stress 
or burnout (5-HTTLPR x work stress or 5-HTTLPR x MBI-GS) with METsum in a 
multivariable model, no statistically significant (p=0.58 and p=0.082, respectively) 
interactions are found.
Table 7. Distribution of the 5-HTTLPR genotype. (Table used under permission from PLOS ONE)
Genotype La/La La/S S/S
N (%) 21 (39.6%) 19 (35.8%) 9 (17.0%)
Mean burnout scores (SD) 0.889 (±0.764) 1.02 (±0.604) 0.951 (±0.499)
Mean depression scores 
(SD)
6.48 (±6.32) 6.05 (±4.94) 6.89 (±4.34)
METsum (SD) 35.3 (±16.2) 36.5 (±22.3) 49.9 (±25.3)
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5 Discussion
Seldom is a disease restricted to only one certain tissue or celltype and the need for 
tools to investigate disorders as a whole grows stronger as more pathway and net-
work information is being gathered (Dobrin et al., 2009).
The inter-tissue pathway analysis and the network analysis are attempts to mod-
el a more complete molecular picture of disease.
It is evident that this kind of study represents the disorder of interest more com-
pletely, compared to investigating tissues separately (as implied by the field of neuro-
imaging (Rigucci, Serafini, Pompili, Kotzalidis, & Tatarelli, 2010)). Studies conduct-
ed using neuroimaging, lesion analysis, and post mortem methodologies, all support 
the model in which the pathophysiology of depression is due to a dysfunction in an 
extended network involving the FCX and anatomically-related limbic, striatal, tha-
lamic and BF structures (Price & Drevets, 2012). Lately, the importance of multid-
iciplinary studies on the function of different brain areas has been emphasized and 
extended to include genome-wide gene expression analysis (Stansberg et al., 2007). 
Some of the studies performed have been further refined to monitor, not only the 
healthy brain, but also include detection of differences in gene expression related to 
phenotype or disorder (Letwin et al., 2006). Despite the amazing achievements of 
work such as the Allen Brain Atlas –project (Lein et al., 2007), it is still, for the time 
being, practically impossible to reliably monitor global three (not to mention four or 
five) dimensional gene expression without spatial interruptions, which means that 
tools are needed to estimate the interactivity and the situation in the “space” in be-
tween the measuring points.
In the inter-tissue pathway and network analyses two already existing tools 
were used, and by careful planning of the input data, intricate hidden networks af-
fected by the clomipramine treatment, were revealed.
In both analysis methods a large number of findings were previously well known 
to the field of psychiatry. These changes may lack novelty value, but instead they 
confer a certain reliability to the methods. The fact that changes in sleep pathways 
were detected and qualified near the top list of disrupted pathways (not present in 
Table 2a or 2b due to p-value cut-off at permuted p≤2,5E-04 in the tables) indicates 
not only that the CLI model really affects sleep (GO:0030431, optimal p=6,61E-04, 
permuted p=0,00723) and the regulation of circadian rhythm (GO:0042752,  opti-
mal p=0,00164, permuted p=0,0161), but it also shows that the present GO databas-
es are becoming extensive and precise enough to distinguish pathways involved in 
very intricate phenomena.
In addition, the most interesting of the novel findings from the two methods con-
sistently combine as the melanosome, detected in the inter-tissue pathway analysis, is 
the primary reservoir of Mn(II) (Cotzias, Papavasiliou, & Miller, 1964; Van Woert, Ni-
cholson, & Cotzias, 1965) that was detected in the inter-tissue network analysis.
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At first glance the proposed central role of melanosomes in the regulation of 
sleep and mood alerts of a secondary effect or of deficiencies in pathway databas-
es. Nevertheless, melanosomes are existent in the brain, where their function is still 
quite unknown, making the finding even more exciting. Lately melanocytes have 
been shown capable of producing classical stress neurotransmitters, neuropeptides 
and hormones, which are secreted to either act locally in a neurotransmitter-like 
manner, or to enter the circulation and affect systemic homeostasis according to en-
docrine model. Actually, many of the products of melanocytes have been previous-
ly linked to the regulation of sleep, mood and stress. Corticotropin releasing factor 
(CRF) and proopiomelanocortin (POMC) that is processed to adrenocorticotropic 
hormone (ACTH), α-MSH and β-endorphin, have both been shown to be central to 
all three phenomena (Plotsky, 1995).  Additional examples of melanocyte neuroen-
docrine activity are their ability to produce and secrete catecholamines, L-DOPA, 
lipocalin-type prostaglandin D synthase (L–PGDS) and the capability to transform 
L-tryptophan to serotonin, N-acetylserotonin and melatonin with its further metab-
olism (Slominski, 2009). Because melanocytes are able to produce L–PGDS, a potent 
inducer of sleep, and produce opioids that regulate respiratory rhythm, it suggests 
that brain melanocytes produce these molecules in vivo to regulate sleep (Colombo, 
Berlin, Delmas, & Larue, 2011).
Furthermore, as the melanosomes are the primary reservoirs of Mn(II) (Cotzias 
et al., 1964; Van Woert et al., 1965), a molecule that was found to have a central role in 
the networks involved in the clomipramine model. Mn(II) is involved in the control 
of mood and sleep, and has been linked to psychiatric traits such as increased anxie-
ty, insomnia and irritability (Calne, Chu, Huang, Lu, & Olanow, 1994; Pal, Samii, & 
Calne, 1999). Further clues of the behavioural effects of Mn(II) can be acquired by ob-
serving manganism (Mn intoxication). In the initial stage of manganism the neuro-
logical symptoms consist of reduced response speed, irritability, intellectual deficits, 
mood changes, and compulsive behaviours, but after a prolonged state of manganism 
the symptoms start to resemble those observed in Parkinsons disease (Roth, 2006).
The research in the cofactors stress and age and their contribution to the vul-
nerability to changes in mood and sleep, is paradigmatically more conventional and 
the experimental designs are not as multidimensional as in the clomipramine mod-
el. Nevertheless, as the experimental designs were based to a higher degree on previ-
ous findings and assumptions, the outcomes were, although not completely unfore-
seen, very precise and add up to the growing knowledge of these phenomena.
The diminished increase in the expression of the plasticity gene BDNF, during 
sleep deprivation, observed in the old animals, correlated well with the age depend-
ent increase in sleep latency and reduced SWA response after the prolonged wake-
fulness. This supports not only the plasticity hypothesis, according to which the ho-
meostatic sleep need is build up due to a plasticity related time dependent increase 
in synaptic strength, but it also explains the reduced sleep need that is accompanied 
by age. The reduction in the SWA response and the higher sleep latency, in the old 
animals, being indicators of a reduced sleep need.
Discussion
63Molecular mechanisms of sleep and mood Research 100 ∙ 2013
National Institute for Health and Welfare
The investigations of regulatory mechanisms, related to sleep deprivation and 
adaptation to stress, were also very productive. The most outstanding genes from the 
experiment in BF were subject to a promoter analysis that revealed a highly signifi-
cant enrichment of the binding site for CREB1. CREB1 has previously been linked to 
both sleep regulation (Graves et al., 2003) and depression (Zubenko et al., 2003). The 
differences in methylation, at the SLC6A4 promoter, between the low work stress 
group and the high stress group, were significant. The results suggest that this coping 
mechanism is responsible for the increased susceptibility for depression observed 
during prolonged periods of stress. Furthermore, during the initial introduction of 
the DNA methylation analysis, in form of direct bisulfite sequencing, two major im-
proving factors were discovered. After the bisulfite conversion the DNA is highly 
degraded and includes mismatches, due to the C→U/T conversion. By using a poly-
merase that lacks the proofreading domain (3’- 5’ exonuclease activity) the PCR of 
the highly degraded DNA can be highly enhanced. Another major improvement, at 
the level of sequence quality, can be achieved by using tailed primers in the PCR and 
the use of primers targeted to these overhangs in the sequencing reaction.
In addition to the results presented here, the studies yielded a vast amount of 
useful knowledge, especially the studies in the clomipramine model, as each tissue 
was also investigated separately on a single gene level, and the results, although not 
directly presented here, are available in the original publications (I, II & III).
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6 Conclusions
This study evinces that stress, sleep and mood are highly interconnected phenome-
na that affect each other and, furthermore, their properties change with age.  The re-
sults demonstrate that the regulatory mechanisms of these phenomena have exten-
sive overlap on a molecular level. In addition, these findings also suggest that coping 
mechanisms exist for the body to deal with extreme situations of high stress and re-
stricted sleep. Whereas these mechanisms have a short-term benefit, prolonged ex-
posure to any of these conditions result in the same mechanisms giving rise to in-
creased susceptibility for disorder.
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